CA2087084C - Esters of acyl carnitines with long-chain aliphatic alcohols and pharmaceutical compositions containing same having antimycotic activity - Google Patents
Esters of acyl carnitines with long-chain aliphatic alcohols and pharmaceutical compositions containing same having antimycotic activity Download PDFInfo
- Publication number
- CA2087084C CA2087084C CA002087084A CA2087084A CA2087084C CA 2087084 C CA2087084 C CA 2087084C CA 002087084 A CA002087084 A CA 002087084A CA 2087084 A CA2087084 A CA 2087084A CA 2087084 C CA2087084 C CA 2087084C
- Authority
- CA
- Canada
- Prior art keywords
- esters
- acid
- candida
- pharmaceutical composition
- fungi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Esters of acyl L-carnitines of general formula (I) (see Formula I) wherein R is a straight or branched acyl group having 2 to 16 carbon atoms, in particular isobutyryl and isovaleryl;
n is an integer comprised between 7 and 15, particularly 10; and, X- is the anion of a pharmacologically acceptable acid are endowed with potent antimycotic activity particularly against yeast life fungi, such as Candida albicans, the aetiologic went of candidiasis and against filamentous fungi, such as Aspergillus fumigatus, the aetiologic agent of aspergillosis.
Orally or parenterally administrable or topically applicable pharmaceutical compositions comprise an ester of formula (I) as active ingredient.
n is an integer comprised between 7 and 15, particularly 10; and, X- is the anion of a pharmacologically acceptable acid are endowed with potent antimycotic activity particularly against yeast life fungi, such as Candida albicans, the aetiologic went of candidiasis and against filamentous fungi, such as Aspergillus fumigatus, the aetiologic agent of aspergillosis.
Orally or parenterally administrable or topically applicable pharmaceutical compositions comprise an ester of formula (I) as active ingredient.
Description
2os~as~
"Esters of acyl carnitines with long-chain aliphatic alcohols and pharmaceutical compositions containing same having antimycotic activity"
The present invention relates to esters of aryl L-carnitines with long-chain aliphatic alcohols, of general formula (I) CH3 0\/CH3 CH \N+ (CH2~, ~X ~ Q
(I) wherein R is a straight or branched acyl group having from 2 to 16, preferably from 4 to 12, carbon atoms, in particular isobutyryl and isovaleryl;
n is an integer comprised between 7 and 15, particularly 10, and X- is the anion of a pharmacologically acceptable acid.
Among the esters of formula (I) isovaleryl L-carnitine undecil ester and isobutyryl L-carnitine undecil ester are particularly preferred.
./.
208'~08~
Therefore, the present invention also relates to orally or parenterally administrable or topically applicable pharmaceutical compositions useful for the treatment of infections such as candidiasis, cryptococcosis and aspergillosis sustained by pathogenic fungi.
Crytpococcosis is an infection of the respiratory tract, generally asymptomatic and benign which may provoke a systemic spread and serious cephalomeningitis in both wasted and even healthy sub,)ects.
The disease is due to the fungus Cr3~ptococcus neoformans (now known as Filobasidiell~ neoformans) widely distributed in nature, which can be transmitted to humans via inhalation.
Candidiasis encompasses a wide range of mycoses varying from common infections of the skin and mucous membranes to life-threatening systemic infections. These infections are due to some strains belonging to the genus Candida, particularly C. icons.
is s is one of the most widely occurring constituents of the microbial flora of various mucosas such as that of vagina, mouth and digestive tract, where under conditions particularly unfavourable to the host but optimal for the fungus growth (such as debilitating affections, prolonged administration of antibiotics and corticosteroids, etc.) it may bring about life-threatening pathologies.
./.
208'7084 The main affections induced by this fungus are: vulvovaginitis, dissemination to the lungs (pneumonia) and other organs such as kidney, spleen, eyes, meninges, liver, intestine and endocardium, as complication of preexisting diseases; thrush frequently occurring in newborns and young adults (characterized by creamy white patches on the buccal mucosa); cutaneous candidiasis and onychomycosis.
Aspergillosis, an infectious disease caused by the inhalation of spores of the genus Aspergillus (fum~'i~at-u~, fl v s , is a serious and invasive pulmonary infection brought about by the growth of a fungal colony which frequently fills preexisting cavities, such as pulmonary abscesses.
Aspergillus spp (e.g. A. ni er may also cause otomycosis. Serious intoxications (mycotoxicosis) in animals, fed on contaminated fodder, are caused by the toxins (aflatoxins) produced by Ate, ,pegillus .
Aspergillus flavu is suspected to cause cirrhosis and liver cancer in humans, in areas wherein foodstuffs are likely to be contaminated by aflatoxins.
./.
2os7as~
The esters of formula (I) may be prepared following two distinct synthesis processes. The first process (illustrated in the synthesis scheme 1 ) comprises the steps consisting of:
(a) halogenating an acyl L-carnitine with a halogenating agent, such as thionyl chloride and oxalyl chloride (molar ratio comprised between 1:1 and 1:4) in an anhydrous organic inert solvent such as acetonitrile or methylene chloride at a temperature comprised between 0°C and 30°C for 1 - 4 hours, concentrating the raw reaction product and using it in the following step;
(b) dissolving the acid chloride of step (a) in an anhydrous organic inert solvent such as acetonitrile or methylene chloride and adding the alcohol diluted in the same solvent at a ratio comprised between 1:1 and 1:2, at a temperatures comprised between 0°C and 30°C for 2 - 10 hours, concentrating the solution and, if needed, purifying the compound by chromatography on silica gel; and ( c ) eluting the product dissolved in water or in an organic solvent on a strongly basic ion exchange resin such as Amberlite IRA.
402 or on a weakly basic ion exchange resin such as Amberlist A
21, activated with the desired HX acid and isolating the end product by lyophilization or concentration.
./.
208'~08~
s The second process (illustrated in the synthesis scheme 2) comprise the steps consisting of:
(a') reacting carnitine or an acyl carnitine inner salt with the relevant alkyl halogenide (preferably bromide or iodide) in an organic anhydrous inert solvent at a temperature comprised between 30°C and 60°C for 8 - 24 hours and then isolating the resulting compound by concentration;
(b') acylating the ester obtained in step (a') with the desired acid chloride by known techniques, in case the starting compound in step (a') is carnitine;
(c') eluting an aqueous or alcoholic solution of the compound of step (a') or (b') on an ion exchange resin, such as Amberlite IRA
402 or Amberlist A 21 activated with the desired I-iX acid.
The anion X- of the pharmacologically acceptable acid is preferably selected from chloride; bromide; iodide; aspartate, particularly acid asparatate; citrate, particularly acid citrate; tartrate;
phosphate, particularly acid phosphate; fumarate, particularly acid fumarate; glycerophosphate; glucosephosphate; lactate; maleate, particularly acid maleate; orotate; oxalate, particularly acid oxalate;
sulphate, particularly acid sulphate; trichloroacetate; trifluoroacetate and methansulphonate.
./.
CH3\ OH CH3\ CI
CH3 N+ ~ -_-~, CH3 N+
CH ~x 0 0 step a /'~CI- 0 R R
step b Rl OH
CH3 ~N+ Y ~ ~R~
CH3 ~ + ~ 1"~ R~
CH3 0 0 step c ~ 0 0 R
R
R = aryl R1 = alkyl having 11 - 16 carbon atoms ./.
s CH3 0' CH \N+ Y ~ + yRl R = H, aryl CH ~ O 0 y = ~ogen \ Rl = alkyl having 11 - 16 carbon atoms R step a CH3 0~
\ 'R
CH3/N+ ' R
ion exchange RCOCI
resin \ \ step c CH3 N+ ~ ~ R~ ~ CH3 ~N+ Y ~ Ri CH~X' 0 0 CH/ Y- 0 0 R
./.
P~ample 1:
PREPARATION OF ISOVALERYL-L-CARNITINE UNDECYL ESTER CHLORIDE
(ST ?22) to A Preparation of isovaleryl-L-carnitine chloride acid chloride.
Isovaleryl-L-carnitine chloride (30 g; 0.106 moles) was suspended in 100 ml anhydrous CH2C12.
The mixture was cooled at 0°C and oxalyl chloride ( 13 ml; 0.15 moles) diluted in 15 ml anhydrous CH2Cl2 was slowly added under stirring.
After 30 minutes at room temperature, a further amount of oxalyl chloride (19 ml; 0.21 moles) diluted in 10 ml anhydrous CH2C12 was added.
The resulting solution was kept under stirring for 2 hours at room temperature, then concentrated under vacuum.
The residue thus obtained was washed twice with anhydrous CH2C12 and concentrated under vacuum.
The raw product thus obtained was used as such in the next reaction.
Steg B: Preparation of isovaleryl-L-carnitine undecyl ester chloride (ST 722).
The acid chloride previously prepared (0.106 moles) was dissolved in anhydrous CHZCl2 (40 ml).
The solution was cooled at 0°C and undecylic acid (35 ml; 0.168 moles) diluted in 35 ml CH2C12 was added in a nitrogen atmosphere.
The solution was kept under stirring at room temperature for 2 hours and then concentrated under vacuum until an oily residue was obtained.
The raw reaction mixture was chromatographed on a silica gel column buffered with 2% Na2HP04, eluting with CH2C12 till complete elution of ./.
20~'~0~~
,o undecylic alcohol and then with CH2C12-MeOH 9:1 till complete elution of the compound.
The pooled fractions were concentrated and gave 28 g of the title compound; Yield 60%.
- 10.5 (c=1% H20)) D
Elementary analysis for C23H4sC1NO4 C% H% Cl% N%
Calculated (anhydrous) 63.3510.63 8.13 3.21 Found 60.87 0.88 8.14 3.29 H20 2.4°r6 HPLC
Column: Spherisorb Cl 5 ~tm t.: 50 °C
Eluant: CH30H/KH2P04 50 mM (65:35) Flow rate: 1 ml/min.
Retention time: 14.82 min NMR CDC13 ~ 5.5 (lH,m,-CH-); 4.2-3.8(4H,m,N+CH2;OCH2);
3.3(9H,S,(CH3)3N+); 2.8(2H,m,CH2C00); 2.2(2H,m,OCOCH2);
CH3 ~CI~
1.6-1.0(22H,m,CH ~ ; (CH2)9CH3); 0.8(6H,d,CH/~ ) EII;AMPLE 2:
PREPARATION OF ISOBUTYRYL-L-CARNITINE UNDECYL ESTER CHLORIDE
(ST 712) /.
208'~D84 The compound was prepared as described in example 1, substituting isobutyryl L-carnitine chloride for isovaleryl L-carnitine chloride. Yield 55%.
- 15.8 (c=1% H20) D
Elementary analysis for CZZH4404NC1 C% H% Cl% N%
Calculated (anhydrous) 62.61 10.51 3.32 8.40 Found 61.77 10.67 3.29 8.17 H20 0.8%
HPLC
Column: Spherisorb Cl (4.6 mm) eluant CH30H-KH2 P04 50 mM 60-40 Flow rate: 1 ml/min Retention time: 14,75 min NMR CDC13 ~ 5.5 (lH,m,CH); 4.2-3.8(4H,m,N+CH2-;OCH2);
OCO
3.3 (9H,s,(CH3)3N+); 2.8(2H,m,CH2C00); 2.5 (lH,m,COCH);
1.5-0.9 (27H,m,CH ; (CH2)9-CH3 CHI
Eaam~les 3-19 The compounds of Examples 3-19 were prepared following the procedures of the previous examples, as apparent to any average expert in organic synthesis. The physico-chemical characteristics of the compounds are summarized in the following table.
./.
,2 208'7084 N N N N N + r. cn z xd~~ O~+ ",~N O~+ ~p 0 m~;~ M d~ +
N~,ppx_M M zV M z N ~; MxUx x "00 ~ N (, N ~ O A N ~ 'G N x C",~ N V N ~ M N N
:.: x M'? p ~ U O ° O U x x ~ U ~: ~c U ~d O U a ,M~' A
x + ~ M N '~ ~ p O U ~ ~ O x N ~" ~ r% ~ N
+: _ _ O ;~xU x ~'~'~ M x x N_~~ x '''Oxv; N ~ ~xN
~ x~uN ~ ~-N~-x ~ ~ ~Mo ~ M_O
M U N ,.: M M (, ~-. N ,., ' ' (, ~, . ' O ~ N V N
z ~; x ~ N ~ M O e-~ N ~i rj ~' U d' + N r. ,~,N, Q . ' M x ~N z .. . NY ~ ~u N ~ ~ .: x .. g zx o xM~.~ o+ o x o+ Nx ~ o Nu a ' o + u~°°
xmN~"' x z Nz:~ x zxux x x ~~° M x z ~~°
U'n::~o V NxcUva~ U NUNU U U~ NOx U Nx~o '.'O'_' .' ~ Va ~° ~ a ~ ~N E ~Nx ~
~ N° Nz ~ ~~x N x ~ x~x ~ x~u~x x ~ ~x N
r' x N x r. ~' x '-' N ..i ~O ~' N N o '~'' M '. (V U x .. a .. .. .. ~, .. .. .. . ~. .. 0 0 a x a .a x x ~o a .a x oo ~ o. ~ ~ O a .o 00 ~ x U
O U N ~ t!~ ~ ~ ~ ~ ~ ~ N ~ O tt~ M M O ~ O t17 ~ M
U O 0~0 N V
N M ~ ~ M
x ~ ~ e~-n O GO Ov 'B
O
y .
V 0o cn op v .~ G
' p y rte..
N
'b O b~ L~° i~o b~ U~°
N N d' 00 Q~ M
x M O O ~ ~-V ~ O~ O~ O ~O
U ~° U '° U "' V °~ U '°
O o O o O o w Z NO ZOOn oZOM o~0~ O~O
Q, "~,~ M '~~' N '~~" N x M '~~' M
N N M N N
us° u~ us x o n ono' r, ~ ,-.
r. ,... r. ,-.
s er t!7 N 00 () 00 v0 d~ N M
~ _ '' x ~
N x ~' d' O N x ~' x C ~ ~ U
a v _i ~ _i 1 _~
X U U U U U
O O O O O
--. ~ r, ~ .-.
~, >, G ~ 0.
v ~ c~ m a O G ~ .~ v N ONO OMO M
W ~ M v--~ er ~ tn W O ~
V ~ (!J Gn ~ Cn 2~~'~UB~
~. .. ~ N ' N +~ ~ c~ M x M N x x N x x z x~x z x ~ ~+ u~ + ~u +'oU
x ~~;~ x ~ ~_M ~z° N z~~ z~~
U N N ~ U N N M V x ~ O x 'v O ~, 'G ~,, 'O
x + a N x + ~ .~ A a x ~ a ~ o ~ x .: o ~ x ~ a .:
a E _ u_~~, ux~
M~~M ~\'Nx~M x~" '~vi M O ~ O M U x ',"r, ~.; x M ~ O a p x N ,~' M O x N
'Y' x EU N ~ a''~,~ c~V~ W t ~~Mfj ~" M~Mf~
"~" er ~ x ~ N 'due M g x~ x M_ d~ M O _~ U dM,' M O .-. U
O ~ N N M O ~ ~1' ~ ~O O + N N ~ O O N N N M ~ N ~ N M
x ~- ~:~ x --Nx~ x zxx~° x~xuu x~xuu ''" p '~ :.: '° V x U V ~ N U U N N U
~gM°
~ Nux ~ x Nu~x~ x ~xz~~~ x z~xx ~c zxx~
V .r N N y0 ~ N N er ~O
r" x N v x N N V ~ V V x .~,, v .r yr yr ~ .r uxN~ ~ Uxxx ~ N~.-ox ~x~~~. ~x~~~, Sri O U ~ N lti O U U U lt~ ,r N N .r V Sri V N ~ O lti U N ~ o V O v M '~ ~ r~
o M oQ y ~ o~ N os 'v v o ~ 0 0 ~c~ c Wo'° .~o ~o M 4J N tn v O b~ b~ b\ b~ b~
N M er N N l~
x O O ~ ~--~ O
_ ~ ~ ~ b\
U ~° oM. 4 U '° U ~° U ~ V c~ U ~°
G o ~' ~' ~' o z~ z~ ~~ zM
""' z ~~r, oo ,~' o, o .... ~ a. ~ n a xN xN xM xN xN
w N
U s V b~ U ~ V ~ V b~
x ~ M
.-. r. N ~ r»
r. ,~ ,~ r. r.
s o ~ o M _M ~~. _M _M
U ~ U U
N o au ~u ~x Du t3 r~ b' , o .~ b~ ~-~ ~o , ~ ,~ , o ;
II V ''' V
, _~ _i _i _i _i U U U U U
O N N N N N
r~ ,.-~ ~ r~
w O y O CJ O O
R
v N v O v v O
y ~ In M O O
W ~ ~ O ~ O ~ O ~~., e'' ,N~, e-V
14 ~~~7~~~
M x . O N i:
ai " N
M ::x :
u N+ ~ x ~ x xox-~ ~ ~~~ ~uu ' a ~~ xx~x xg~ x ~
.z~ ~~ '~~M~ ,~u.~ ' x x + + ~
+ N ~
o i ~ ~
~:x~~ ~ y ~ +
z.~ Nu zx zx N' ' , .
~ ~N.~o ~ ~N ~x, ~ ~:M
x.~ ~:v'a xx M
_ _ ~ ~r d~ _ yr N e--~ '~' ,~'. U _ . x N (,J v~
( ) lf\N .'N ~~O x ~~1N~0 ~~N ~
ch ~ ' O
M ~ ~
~ x U d~ ~ V d~
z O M V U ~ ~ M M M O x O
_M
-.
M x ~ . ~: ~ ,~ '~: :: Q N
O x ov p N ~ a M ,~ .
~: ' ' ~
N
O x NU V _ O N N Nx O N NCO N
x O NU ~O .~ xux xu u N~' xx ~ u x x xN x~
x ~~ U
l ~
Q
U U O .N U c~n U Q U U (_~
U U ~ M U Q U ~
N ~ ~ ~ ''.~'~ N N M C~ x ~ f~j ~ ~ fy ~ M ,.Mr ~ N x xxxx~" xx~u-~" ~xxx~ xxx~bu e-~ U N ~ r' U N V ~ r' V N N ~ a V v ~
e~ M 'r M
W + a"0 O Iw + ~ x) ~ W + a0 v0 W + 00 x1 N x x O~ ~ x lf~ z N N In z N U ~ ~ In z N r-. In z N U .~
~ U O U
ca N ~ O N
x y- .
P . .-In G
ll~ l~ y .4i y v O ~ s s s N O ~ ~C
x ~ 0 0 0 V o a'o .o U ~ U ~ U ~ U ~
W ~ e~ ~r O o Q o o o ~~ ~~
z N d' ~O
Q xc'n xM 'xN xN
W d' M ~O o0 V s U s U b~ V b~
x N ~ N
N e-~ N r' r. e-y . e-.
(J d~ O~ O M
x O
N Nx mO my Ox D
N ~"' N
i ~ i N
O
V V
V
_i _n X U U U U
,..., ,~ ~ W
r. r '' ' o v x > ~ >
sa, o .o .o v 00 o r-y O O
iC M ~ if f ~O
W r.. '" r, '" .-. '-' ,_, r.
~
..
~+ N ~ ~ zN::°~
z ,x ~;N~°o x ~xx M
N N '"~"
x xo~~v~ o ~NuxA + ~~~u o ~, --o ~ ~ N -= v a .: ,Z Q N M
M N ~ ~ V a i~s ~ UI b x ~ iv N ~ U
_M x N M
N N .O ~ x N ~ VO ~.,; ~ M a x N .xx xux ~ -- V
x ~~u,~ ~. oux x ~ xou xx ~~, ~ NEo~~ ~+ ~ ~
N ~ 'C
U OO ~'~N~~ xNx N N O x N is U N ~
u~
x+ ~x~~ .:: xv~V.
O + O O ~ N M U iZ rj U N c.~ O ~ M r, Ov U z M ~ ~ oo U U x ~ QU U U~ U cYi " .N °.
~ ~~ ~ M ~; ~ ~,~o ~x x M a -= x x ~ MN~~cx x ~ ~~~.: x Nuu~c ~O M N_ M _N _~ x N .~
~.~~Nx~~~ .~ ~UN~.~ ~ uxx o0 U7 M .~ N U ~ O v0 d~ ... r ~ .. ~ti O U U .C D
~ n ~ M
n x ~ M M uj G C
O O
G! CJ
r 4! 0!
'L3 "a o ,L~° b~
ON ~
x ~ O .~
V ono O pp Q o0 O o Z o z o v~ U
'o Z n~ ~d'~ O
~M
N N O
V O U
"~, [~ p~ N
O
N O~
V
.. ..
N f..r O ~ ,~, M ~ d' x ~j II ~ II ~ II
V V V
~r ~r w .d m y '~ _~
X v .u ~ io V U
ate,. rte. ~ w ~
Q O o0 N
y v V
O O
N
O
W ~ ~ O pp O p~
V (r a 16 O
O O
'~r x O
x x O ~ M
x x ~ o o x M
x ' ~
O '~' ~ ~ d clvj d' M
z '~ ~ :~ ~ :~ ~ -~ z ' .., w- a x ~ ~ ~ ~ ~ ~ ~ U
cu N E N ~ N ~ ~ \
O O O N ~
~ tn ~ tn d, ~ d' ~ d' ~ ~ d~
~ O O O ~ O
o " N " N _~ , ' 'd' N ~ ~ U
cn O '~ ~ ~ p "~~ ~ "~~ cn '~
~
_~ . . ~ .fl ~ \ ~ o .
~, \~. ~ o ~ x\ x ~
o x \ x \ N~
x\ ~ ~ o .~ 0 _ ~ a~ O a~ ~ ~ v M ~ V U m x o ~ x~ ~a ~
M
o .~ . ~~ ~ ~ x ~ U U o z n Zzo cn Uo cn o cn z o c U ,-~, ~ ~, ~ ~. ~ ~.
~
,'.fl3 0 ~ 0 3 ~ -H ~ U ~ ~ U ~ ~ U H ~ ,.., 0 -H -H W 0 ~
U E-~
~a U E-H ..fl ~ a ~ a~
~ U E E E
2~8'~~84 ASSESSMENT OF BEHAVIOUR AND MORTALITY IN MICE.
The assessment of normal behaviour in mice was carned out following S.
Irwin's method (Psychopharmacologia, 13, 222 [1968]). This method allows alterations in some behavioural, neurophysiologic and neurovegetative parameters to be detected, which are directly observable by the researcher.
The study was conducted using male Crl:(CD-1)(ICR)BR mice (Charles River-Italy) weighing 22-25 g, following oral administration of the compounds suspended in carboxymethylcellulose (0.5% by weight in H20) to groups of 4 animals/dose.
The animals were continously kept under observation for five hours following treatment and twice a day in the subsequent five days. Mortality was also observed during the overall test period.
Assessment of behaviour and mortalit3r in mice.
Compound ose Symptoms Mortality ST 722 1000 salivation,diarrhoea O/4 ./.
,$ 208'~08~
IMMUNOTOgICOLOGICAL STUDIES
Some immunotoxicological results after oral ST 722 administration in mice are described hereinafter:
Test 1: Evaluation of the "in vitro-es vivo" effect of repeated oral administrations of ST 722 on the primary antibody produc-tion (Jerne test) in the spleen of SRBC (Sheep Red Blood Cells) immunized mice.
Experimental procedure Male BFI mice (C. River) aged 8 weeks (6 animals each group) were utilized.
The substance (ST 722) was administered per os at the dose of 100 mg/kg/day from day -2 through day +2 (immunization at day 0).
The animals were immunized by intraperitoneal route with a con-centration of 1.0x108 cells/mouse in 0.2 ml of sterile saline.
Five days later, spleens to be submitted to teasing process were removed from the animals sacrificed by cervical dislocation.
After standardization at l.OxlO~ cells/ml, the splenocytes (0.1 ml) were mixed with warm agar-Hank's (2 ml) and 10% SRBC in PBS
(0.2 ml) and seeded in Petri dishes (samples tested in triplicates) and incubated at 37°C for 60 min.
After addition of complement (2 ml of guinea pig serum diluted 1:10 2 5 in Tris buffer), samples were further incubated at 37°C for 30 min.
To block the haemolysis reaction, the Petri dishes were cooled at 4°C
,087084 and the haemolysis plaques were counted.
The antibody response to SRBC is expressed as number of plaque forming cells (PFC) per 1.0x106 splenocytes as well as per spleen.
Results The results indicated that the repeated (5 consecutive days) oral administrations of ST 722 did not cause a statistically significant modification in PFC number after the antigenic challenge (Table 1).
These data exclude the existence of an immunotoxic effect on the antibody-producer B lymphocytes.
The weight of the lymphoid organs (spleen and thymus) did not show values relating to a toxic effect as well (Tab. 1).
Table 1 Primary antibody production (Jerne test). Evaluation of the number of PFC (x~+S.E.) in the spleen of mice immunized with SRBC and treated per os with ST 722 at the dose of 100 mg/kg/day from day -2 through day +2 (immunization at day 0).
Body Spleen Thymus PFC/ 106 PFC/
Treatment weight weight weight cells spleen (g1 (mg) (mg) Control 25.33 95.50 64.00 20232 34228 10.38 3.19 1.51 5064 ST ?22 25.12 94.33 59.50 26134 44440 0.77 4.12 3.62 6087 ~~s7o~4 Test 2: Evaluation of the effect of repeated oral administrations of 8T 722 on the weight of marine lymphoid organs (spleen and thymus).
Eacperimental procedure Male BFI mice (C. River) aged 7 weeks (7-8 animals each group) were orally treated with the substance ST 722 at the dose of 100 mg/kg/day for 7 consecutive days. Twenty-four hours after the last administration, the animals were sacrificed, the organs removed and weighed.
Results The performed treatment did not provoke any immunotoxic effect on the parameters examined (Table 2).
Table 2 Weight (xtS.E.) of marine lymphoid organs after repeated treatment oral of the animals with the substance ST 722 (100 mg/kg/day for 7 consecutive days).
Treatment Body weights Spleen weights Thymus weights (g) (mg) (mg) Control 24.000.68 79.633.31 51.882.72 ST 722 22.740.37 77.882.38 52.883.20 a = mean value (x-+E.S.) of 7-8 samples.
208'084 Test 3: Evaluation of the effect of repeated oral administrations of ST 722 on the body, spleen and thymus weight, and on the splenocyte concentration In mice.
Experimental procedure Male B~F1 mice (C. River) aged 10 weeks (5 animals each group) were orally treated with the substance ST 722 at the dose of 100 mg/kg/day for 5 consecutive days. Twenty-four hours after the last administration, the animals were sacrificed, the organs removed and IO weighed, and the splenocyte number determined.
Results The results, reported in Table 3, showed a lack of specific im-munotoxic effects on the considered parameters following the scheduled ST 722 treatment.
Table 3 Weight of lymphoid organs and spleen concentration after repeated oral treatments of mice with the substance ST 722 (100 mg/kg/day for 5 consecutive days).
Treatment Body weights Splenoc. numberb Spleen weights Thymus weights (g) (mg) (x10-(mg) Control 27.700.48 75.752.36 4I.75f3.59 7.90 ST 722 26.500.53 73.253.84 38.803.01 7.85 a = mean value (x_+S.E.) of 5 samples.
b = value from 5 pooled samples.
Test 4: Evaluation of the effect of repeated oral administrations of ST ?22 on the peritoneal macrophage number in mice.
Experimental procedure Male B6D2Fi mice (C. River) aged 10 weeks (6 animals each group) were orally treated with the substance ST 722 at the dose of 100 mg/kg/day for 5 consecutive days. Twenty-four hours after the last administration, the animals were sacrificed, the peritoneal exudate cells (PEC ) collected and the macrophage number determined.
Results No toxic effect has been observed in PEC macrophage population; on the contrary, we measured an increase of about 60% in the peritoneal macrophages number of mice treated with the substance ST 722 (Table 4).
Table 4 Peritoneal macrophage (Mrs) number in mice treated with ST
?22 (100 mg/kg/day for 5 consecutive days).
Treatment Body weightPEC/mouseb PEC Mmb PEC Mm/mouseb a (X1O~6) (%) (X1O-s) Control 28.070.63 2.14 53 1.13 2 5 ST 722 28.131.30 2.86 63 1.80 a = mean value (~S.E.) of 6 animals.
b = Value from 6 pooled samples.
Evaluation of the Minimal Inhibitory Concentration (MIC) of 16 new substances for yeast and yeast-like strains.
Experimental procedure The following strains were used (the number of strains is in brack-ets):
Candida (13); Criptococcus (2); Saccharomyces (I); Torulopsis (I).
The tested substances were: ST 712, ST 722, ST 982, ST 983, ST
1000, ST 1001, ST 1032, ST 1033, ST 1034, ST 1036, ST 1037, ST
1038, ST 1050, ST 1051, ST 1052, ST 1053.
Yeast Nitrogen Base supplemented with 0.15% asparagine and 1.0%
glucose (as carbon source) was the medium utilized in the assays.
This medium was buffered with 0.165 M 2-(N-morpholino) propane sulfonic acid (MOPS), a non-chelating buffer.
The test was performed following the standard microdilution procedure and the inoculum suggestions of Pfaller (PFALLER M., RINALDI M.G., GALGIANI J.N., BARTLETT M.S., BODY B.A., ESPINEL-INGROFF A., FROMTLING R.A., HALL G.S., HUGHES G.E., ODDS F.C.
and SUGAR A.M.,1990. Collaborative investigation of variables in 2 0 susceptibility testing of yeasts. Antimicrob. Agents Chemother. Sept.
34, 9: 1648-1654) with COOK's modifications (COOK R., Mc IN'I'YRE
K.A. and GALGIANI J.M.,1990. Effect of incubation temperature, inoculum size, and medium on agreement of macro-and microdilu tion broth susceptibility test, results for yeasts. Antimicrob. Agents 2 5 Chemother. Avg. 34, 8:1542-1545).
The inoculum was prepared from an overnight broth culture (a 48-hour culture only for Cryptococcus) in Sabouraud broth and ap-X08'7084 propriately diluted to yield a final suspension containing approximately 5.0x106 Colony Forming Units per mI (CFU/ml), when compared to the Mc Farland's standard control (BRAY W.E., Clinical Laboratory Methods, 5th Ed. C.V. MOSBY, St. Louis, Mo, 1957).
After further diluting ( 1:50), a 0.150-~,1 volume of such fungal suspensions and an equal volume of the substance solutions were distributed into each well of a microtiter plate (96 wells, round bottom). Such a procedure eventually allowed for an "in vitro"
antimycotic activity assay utilizing final fungal inocula of approximately 5.0x104 CFU/ml.
lNaC evaluation After incubating the microtiter plates for 48 hours at 35°C, the MIC
for each strain was determined, which is defined as the lowest concentration of the test substance where no visible fungal growth occurs.
N~'C evaluation The minimal fungicidal concentration was evaluated by spot transferring onto Petri dishes, containing Sabouraud agar, 0.01-ml volumes of all the samples showing no visible fungal growth.
After incubation for 48 hours at 35°C, the MFC was determined, which is defined as the lowest concentration of the test substance that does not allow growth of agar subcultures.
Results The MIC values, determined after incubating samples for 48 hours at 35°C, and illustrated in Table 1-6, are exactely equal to MFC values (data not shown), proving that these substances possess a lytic and not a simple antiproliferative activity against the tested strains.
26 ~~~~0~~
Table 1 Minimal Inhibitory Concentration (mcg/ml) of 5 Isovaleryl L-Carnitine esters for yeast-like fungi.
ST ST ST ST ST
Strains 10Q2 722 10.1710~i31001 Candida albicaris (562) n.d. 3.12 1.56 1,56 3.12 Candida albicans (A 54) n.d. 3.12 1.56 1.56 3.12 Cartdida albicans (ATCC 2091) n.d. 3.12 1.56 3.12 6.25 Candida albicans (Ca 2) n.d. 1.56 1.56 n.d. 3.12 Candida aibicans (PG) 25 3.12 3.12 3.12 6.25 Candida aIbicans (ISS 1) 25 1.56 3.12 1.56 12.5 2 Candida glabrata (ISS 1 ) n. d. 6.25 3.12 3.12 6.25 Candida guilItermondii (ISS 1) n.d. 6.25 6.25 6.25 6.25 Candida krusei (ISS 1) n.d. 3.12 1.56 3.12 6.25 Candida parapsilosis (ISS 1) n.d. 6.25 3.12 3.12 6.25 Candida pseudoLropicalis (EC n.d. 6.25 6.25 3.12 12.5 1) Candida tropicalis (5705) n.d. 3.12 3.12 3.12 6.25 Candida tropicalis (ISS 1) 12.5 3.12 3.12 3.12 12.5 Cryptococcus neoformans (4711) n.d. 1.56 0.78 0.78 1.56 Cryptococcus neoformans (ISS 50 3.12 1.56 1.56 3.12 1) Saccharomyces cereuisiae (ATCC 100 3.12 3.12 3.12 6.25 7752) Torulopsis candida (D.S.) n.d. 6.25 3.12 3.12 6.25 n.d. = not determined.
20~'~Qg~
Table 2 Mean MIC values (mcg/ml) of 5 Isovaleryl L-Carnitine esters for yeast-like fungi.
Compound Mean MIC values* Tested Resistant strains strains (MIC > 100) ST 1032 42.50 5 0 ST 722 3.76 17 0 ST 103? 2.80 17 0 ST 1033 2.70 17 0 ST 1001 6.24 17 0 * = Mean MIC values versus susceptible strains.
_. 28 ~o~~os~
Table 3 Minimal Inhibitory Concentration (mcg/ml) of 6 Undecyl L-Carnitine esters for yeast-like fungi.
Strains ST ST ST ST ST ST
Candida aIbicans (562) 12.5 1.56 1.56 n.d. n.d. n.d.
Candida, albicans (A 54) 12.5 1.56 1.56 6.25 > > 100 Candida, albicans (ATCC 2091) 12.5 1.56 1.56 n.d. n.d. n.d.
Candida albicans (Ca 2) 6.25 1.56 1.56 1.56 > > 100 Candida. albicans (PG) 12.5 3.12 3.12 n.d. n.d. n.d.
Candida. albicans (ISS 1) n.d. 1.56 1.56 3.12 n.d. n.d.
Candida, glabrata (ISS 1) n.d. 3.12 3.12 6.25 n.d. n.d.
Candida. guilIiermondii (ISS n.d. 6.25 6.25 6.25 n.d. n.d.
1) Candida krusei (ISS 1) n.d. 1.56 1.56 1.56 n.d. n.d.
2 Candida parapsiIosis (ISS 1) n.d. 6.25 6.25 6.25 n.d. n.d.
The present invention relates to esters of aryl L-carnitines with long-chain aliphatic alcohols, of general formula (I) CH3 0\/CH3 CH \N+ (CH2~, ~X ~ Q
(I) wherein R is a straight or branched acyl group having from 2 to 16, preferably from 4 to 12, carbon atoms, in particular isobutyryl and isovaleryl;
n is an integer comprised between 7 and 15, particularly 10, and X- is the anion of a pharmacologically acceptable acid.
Among the esters of formula (I) isovaleryl L-carnitine undecil ester and isobutyryl L-carnitine undecil ester are particularly preferred.
./.
208'~08~
Therefore, the present invention also relates to orally or parenterally administrable or topically applicable pharmaceutical compositions useful for the treatment of infections such as candidiasis, cryptococcosis and aspergillosis sustained by pathogenic fungi.
Crytpococcosis is an infection of the respiratory tract, generally asymptomatic and benign which may provoke a systemic spread and serious cephalomeningitis in both wasted and even healthy sub,)ects.
The disease is due to the fungus Cr3~ptococcus neoformans (now known as Filobasidiell~ neoformans) widely distributed in nature, which can be transmitted to humans via inhalation.
Candidiasis encompasses a wide range of mycoses varying from common infections of the skin and mucous membranes to life-threatening systemic infections. These infections are due to some strains belonging to the genus Candida, particularly C. icons.
is s is one of the most widely occurring constituents of the microbial flora of various mucosas such as that of vagina, mouth and digestive tract, where under conditions particularly unfavourable to the host but optimal for the fungus growth (such as debilitating affections, prolonged administration of antibiotics and corticosteroids, etc.) it may bring about life-threatening pathologies.
./.
208'7084 The main affections induced by this fungus are: vulvovaginitis, dissemination to the lungs (pneumonia) and other organs such as kidney, spleen, eyes, meninges, liver, intestine and endocardium, as complication of preexisting diseases; thrush frequently occurring in newborns and young adults (characterized by creamy white patches on the buccal mucosa); cutaneous candidiasis and onychomycosis.
Aspergillosis, an infectious disease caused by the inhalation of spores of the genus Aspergillus (fum~'i~at-u~, fl v s , is a serious and invasive pulmonary infection brought about by the growth of a fungal colony which frequently fills preexisting cavities, such as pulmonary abscesses.
Aspergillus spp (e.g. A. ni er may also cause otomycosis. Serious intoxications (mycotoxicosis) in animals, fed on contaminated fodder, are caused by the toxins (aflatoxins) produced by Ate, ,pegillus .
Aspergillus flavu is suspected to cause cirrhosis and liver cancer in humans, in areas wherein foodstuffs are likely to be contaminated by aflatoxins.
./.
2os7as~
The esters of formula (I) may be prepared following two distinct synthesis processes. The first process (illustrated in the synthesis scheme 1 ) comprises the steps consisting of:
(a) halogenating an acyl L-carnitine with a halogenating agent, such as thionyl chloride and oxalyl chloride (molar ratio comprised between 1:1 and 1:4) in an anhydrous organic inert solvent such as acetonitrile or methylene chloride at a temperature comprised between 0°C and 30°C for 1 - 4 hours, concentrating the raw reaction product and using it in the following step;
(b) dissolving the acid chloride of step (a) in an anhydrous organic inert solvent such as acetonitrile or methylene chloride and adding the alcohol diluted in the same solvent at a ratio comprised between 1:1 and 1:2, at a temperatures comprised between 0°C and 30°C for 2 - 10 hours, concentrating the solution and, if needed, purifying the compound by chromatography on silica gel; and ( c ) eluting the product dissolved in water or in an organic solvent on a strongly basic ion exchange resin such as Amberlite IRA.
402 or on a weakly basic ion exchange resin such as Amberlist A
21, activated with the desired HX acid and isolating the end product by lyophilization or concentration.
./.
208'~08~
s The second process (illustrated in the synthesis scheme 2) comprise the steps consisting of:
(a') reacting carnitine or an acyl carnitine inner salt with the relevant alkyl halogenide (preferably bromide or iodide) in an organic anhydrous inert solvent at a temperature comprised between 30°C and 60°C for 8 - 24 hours and then isolating the resulting compound by concentration;
(b') acylating the ester obtained in step (a') with the desired acid chloride by known techniques, in case the starting compound in step (a') is carnitine;
(c') eluting an aqueous or alcoholic solution of the compound of step (a') or (b') on an ion exchange resin, such as Amberlite IRA
402 or Amberlist A 21 activated with the desired I-iX acid.
The anion X- of the pharmacologically acceptable acid is preferably selected from chloride; bromide; iodide; aspartate, particularly acid asparatate; citrate, particularly acid citrate; tartrate;
phosphate, particularly acid phosphate; fumarate, particularly acid fumarate; glycerophosphate; glucosephosphate; lactate; maleate, particularly acid maleate; orotate; oxalate, particularly acid oxalate;
sulphate, particularly acid sulphate; trichloroacetate; trifluoroacetate and methansulphonate.
./.
CH3\ OH CH3\ CI
CH3 N+ ~ -_-~, CH3 N+
CH ~x 0 0 step a /'~CI- 0 R R
step b Rl OH
CH3 ~N+ Y ~ ~R~
CH3 ~ + ~ 1"~ R~
CH3 0 0 step c ~ 0 0 R
R
R = aryl R1 = alkyl having 11 - 16 carbon atoms ./.
s CH3 0' CH \N+ Y ~ + yRl R = H, aryl CH ~ O 0 y = ~ogen \ Rl = alkyl having 11 - 16 carbon atoms R step a CH3 0~
\ 'R
CH3/N+ ' R
ion exchange RCOCI
resin \ \ step c CH3 N+ ~ ~ R~ ~ CH3 ~N+ Y ~ Ri CH~X' 0 0 CH/ Y- 0 0 R
./.
P~ample 1:
PREPARATION OF ISOVALERYL-L-CARNITINE UNDECYL ESTER CHLORIDE
(ST ?22) to A Preparation of isovaleryl-L-carnitine chloride acid chloride.
Isovaleryl-L-carnitine chloride (30 g; 0.106 moles) was suspended in 100 ml anhydrous CH2C12.
The mixture was cooled at 0°C and oxalyl chloride ( 13 ml; 0.15 moles) diluted in 15 ml anhydrous CH2Cl2 was slowly added under stirring.
After 30 minutes at room temperature, a further amount of oxalyl chloride (19 ml; 0.21 moles) diluted in 10 ml anhydrous CH2C12 was added.
The resulting solution was kept under stirring for 2 hours at room temperature, then concentrated under vacuum.
The residue thus obtained was washed twice with anhydrous CH2C12 and concentrated under vacuum.
The raw product thus obtained was used as such in the next reaction.
Steg B: Preparation of isovaleryl-L-carnitine undecyl ester chloride (ST 722).
The acid chloride previously prepared (0.106 moles) was dissolved in anhydrous CHZCl2 (40 ml).
The solution was cooled at 0°C and undecylic acid (35 ml; 0.168 moles) diluted in 35 ml CH2C12 was added in a nitrogen atmosphere.
The solution was kept under stirring at room temperature for 2 hours and then concentrated under vacuum until an oily residue was obtained.
The raw reaction mixture was chromatographed on a silica gel column buffered with 2% Na2HP04, eluting with CH2C12 till complete elution of ./.
20~'~0~~
,o undecylic alcohol and then with CH2C12-MeOH 9:1 till complete elution of the compound.
The pooled fractions were concentrated and gave 28 g of the title compound; Yield 60%.
- 10.5 (c=1% H20)) D
Elementary analysis for C23H4sC1NO4 C% H% Cl% N%
Calculated (anhydrous) 63.3510.63 8.13 3.21 Found 60.87 0.88 8.14 3.29 H20 2.4°r6 HPLC
Column: Spherisorb Cl 5 ~tm t.: 50 °C
Eluant: CH30H/KH2P04 50 mM (65:35) Flow rate: 1 ml/min.
Retention time: 14.82 min NMR CDC13 ~ 5.5 (lH,m,-CH-); 4.2-3.8(4H,m,N+CH2;OCH2);
3.3(9H,S,(CH3)3N+); 2.8(2H,m,CH2C00); 2.2(2H,m,OCOCH2);
CH3 ~CI~
1.6-1.0(22H,m,CH ~ ; (CH2)9CH3); 0.8(6H,d,CH/~ ) EII;AMPLE 2:
PREPARATION OF ISOBUTYRYL-L-CARNITINE UNDECYL ESTER CHLORIDE
(ST 712) /.
208'~D84 The compound was prepared as described in example 1, substituting isobutyryl L-carnitine chloride for isovaleryl L-carnitine chloride. Yield 55%.
- 15.8 (c=1% H20) D
Elementary analysis for CZZH4404NC1 C% H% Cl% N%
Calculated (anhydrous) 62.61 10.51 3.32 8.40 Found 61.77 10.67 3.29 8.17 H20 0.8%
HPLC
Column: Spherisorb Cl (4.6 mm) eluant CH30H-KH2 P04 50 mM 60-40 Flow rate: 1 ml/min Retention time: 14,75 min NMR CDC13 ~ 5.5 (lH,m,CH); 4.2-3.8(4H,m,N+CH2-;OCH2);
OCO
3.3 (9H,s,(CH3)3N+); 2.8(2H,m,CH2C00); 2.5 (lH,m,COCH);
1.5-0.9 (27H,m,CH ; (CH2)9-CH3 CHI
Eaam~les 3-19 The compounds of Examples 3-19 were prepared following the procedures of the previous examples, as apparent to any average expert in organic synthesis. The physico-chemical characteristics of the compounds are summarized in the following table.
./.
,2 208'7084 N N N N N + r. cn z xd~~ O~+ ",~N O~+ ~p 0 m~;~ M d~ +
N~,ppx_M M zV M z N ~; MxUx x "00 ~ N (, N ~ O A N ~ 'G N x C",~ N V N ~ M N N
:.: x M'? p ~ U O ° O U x x ~ U ~: ~c U ~d O U a ,M~' A
x + ~ M N '~ ~ p O U ~ ~ O x N ~" ~ r% ~ N
+: _ _ O ;~xU x ~'~'~ M x x N_~~ x '''Oxv; N ~ ~xN
~ x~uN ~ ~-N~-x ~ ~ ~Mo ~ M_O
M U N ,.: M M (, ~-. N ,., ' ' (, ~, . ' O ~ N V N
z ~; x ~ N ~ M O e-~ N ~i rj ~' U d' + N r. ,~,N, Q . ' M x ~N z .. . NY ~ ~u N ~ ~ .: x .. g zx o xM~.~ o+ o x o+ Nx ~ o Nu a ' o + u~°°
xmN~"' x z Nz:~ x zxux x x ~~° M x z ~~°
U'n::~o V NxcUva~ U NUNU U U~ NOx U Nx~o '.'O'_' .' ~ Va ~° ~ a ~ ~N E ~Nx ~
~ N° Nz ~ ~~x N x ~ x~x ~ x~u~x x ~ ~x N
r' x N x r. ~' x '-' N ..i ~O ~' N N o '~'' M '. (V U x .. a .. .. .. ~, .. .. .. . ~. .. 0 0 a x a .a x x ~o a .a x oo ~ o. ~ ~ O a .o 00 ~ x U
O U N ~ t!~ ~ ~ ~ ~ ~ ~ N ~ O tt~ M M O ~ O t17 ~ M
U O 0~0 N V
N M ~ ~ M
x ~ ~ e~-n O GO Ov 'B
O
y .
V 0o cn op v .~ G
' p y rte..
N
'b O b~ L~° i~o b~ U~°
N N d' 00 Q~ M
x M O O ~ ~-V ~ O~ O~ O ~O
U ~° U '° U "' V °~ U '°
O o O o O o w Z NO ZOOn oZOM o~0~ O~O
Q, "~,~ M '~~' N '~~" N x M '~~' M
N N M N N
us° u~ us x o n ono' r, ~ ,-.
r. ,... r. ,-.
s er t!7 N 00 () 00 v0 d~ N M
~ _ '' x ~
N x ~' d' O N x ~' x C ~ ~ U
a v _i ~ _i 1 _~
X U U U U U
O O O O O
--. ~ r, ~ .-.
~, >, G ~ 0.
v ~ c~ m a O G ~ .~ v N ONO OMO M
W ~ M v--~ er ~ tn W O ~
V ~ (!J Gn ~ Cn 2~~'~UB~
~. .. ~ N ' N +~ ~ c~ M x M N x x N x x z x~x z x ~ ~+ u~ + ~u +'oU
x ~~;~ x ~ ~_M ~z° N z~~ z~~
U N N ~ U N N M V x ~ O x 'v O ~, 'G ~,, 'O
x + a N x + ~ .~ A a x ~ a ~ o ~ x .: o ~ x ~ a .:
a E _ u_~~, ux~
M~~M ~\'Nx~M x~" '~vi M O ~ O M U x ',"r, ~.; x M ~ O a p x N ,~' M O x N
'Y' x EU N ~ a''~,~ c~V~ W t ~~Mfj ~" M~Mf~
"~" er ~ x ~ N 'due M g x~ x M_ d~ M O _~ U dM,' M O .-. U
O ~ N N M O ~ ~1' ~ ~O O + N N ~ O O N N N M ~ N ~ N M
x ~- ~:~ x --Nx~ x zxx~° x~xuu x~xuu ''" p '~ :.: '° V x U V ~ N U U N N U
~gM°
~ Nux ~ x Nu~x~ x ~xz~~~ x z~xx ~c zxx~
V .r N N y0 ~ N N er ~O
r" x N v x N N V ~ V V x .~,, v .r yr yr ~ .r uxN~ ~ Uxxx ~ N~.-ox ~x~~~. ~x~~~, Sri O U ~ N lti O U U U lt~ ,r N N .r V Sri V N ~ O lti U N ~ o V O v M '~ ~ r~
o M oQ y ~ o~ N os 'v v o ~ 0 0 ~c~ c Wo'° .~o ~o M 4J N tn v O b~ b~ b\ b~ b~
N M er N N l~
x O O ~ ~--~ O
_ ~ ~ ~ b\
U ~° oM. 4 U '° U ~° U ~ V c~ U ~°
G o ~' ~' ~' o z~ z~ ~~ zM
""' z ~~r, oo ,~' o, o .... ~ a. ~ n a xN xN xM xN xN
w N
U s V b~ U ~ V ~ V b~
x ~ M
.-. r. N ~ r»
r. ,~ ,~ r. r.
s o ~ o M _M ~~. _M _M
U ~ U U
N o au ~u ~x Du t3 r~ b' , o .~ b~ ~-~ ~o , ~ ,~ , o ;
II V ''' V
, _~ _i _i _i _i U U U U U
O N N N N N
r~ ,.-~ ~ r~
w O y O CJ O O
R
v N v O v v O
y ~ In M O O
W ~ ~ O ~ O ~ O ~~., e'' ,N~, e-V
14 ~~~7~~~
M x . O N i:
ai " N
M ::x :
u N+ ~ x ~ x xox-~ ~ ~~~ ~uu ' a ~~ xx~x xg~ x ~
.z~ ~~ '~~M~ ,~u.~ ' x x + + ~
+ N ~
o i ~ ~
~:x~~ ~ y ~ +
z.~ Nu zx zx N' ' , .
~ ~N.~o ~ ~N ~x, ~ ~:M
x.~ ~:v'a xx M
_ _ ~ ~r d~ _ yr N e--~ '~' ,~'. U _ . x N (,J v~
( ) lf\N .'N ~~O x ~~1N~0 ~~N ~
ch ~ ' O
M ~ ~
~ x U d~ ~ V d~
z O M V U ~ ~ M M M O x O
_M
-.
M x ~ . ~: ~ ,~ '~: :: Q N
O x ov p N ~ a M ,~ .
~: ' ' ~
N
O x NU V _ O N N Nx O N NCO N
x O NU ~O .~ xux xu u N~' xx ~ u x x xN x~
x ~~ U
l ~
Q
U U O .N U c~n U Q U U (_~
U U ~ M U Q U ~
N ~ ~ ~ ''.~'~ N N M C~ x ~ f~j ~ ~ fy ~ M ,.Mr ~ N x xxxx~" xx~u-~" ~xxx~ xxx~bu e-~ U N ~ r' U N V ~ r' V N N ~ a V v ~
e~ M 'r M
W + a"0 O Iw + ~ x) ~ W + a0 v0 W + 00 x1 N x x O~ ~ x lf~ z N N In z N U ~ ~ In z N r-. In z N U .~
~ U O U
ca N ~ O N
x y- .
P . .-In G
ll~ l~ y .4i y v O ~ s s s N O ~ ~C
x ~ 0 0 0 V o a'o .o U ~ U ~ U ~ U ~
W ~ e~ ~r O o Q o o o ~~ ~~
z N d' ~O
Q xc'n xM 'xN xN
W d' M ~O o0 V s U s U b~ V b~
x N ~ N
N e-~ N r' r. e-y . e-.
(J d~ O~ O M
x O
N Nx mO my Ox D
N ~"' N
i ~ i N
O
V V
V
_i _n X U U U U
,..., ,~ ~ W
r. r '' ' o v x > ~ >
sa, o .o .o v 00 o r-y O O
iC M ~ if f ~O
W r.. '" r, '" .-. '-' ,_, r.
~
..
~+ N ~ ~ zN::°~
z ,x ~;N~°o x ~xx M
N N '"~"
x xo~~v~ o ~NuxA + ~~~u o ~, --o ~ ~ N -= v a .: ,Z Q N M
M N ~ ~ V a i~s ~ UI b x ~ iv N ~ U
_M x N M
N N .O ~ x N ~ VO ~.,; ~ M a x N .xx xux ~ -- V
x ~~u,~ ~. oux x ~ xou xx ~~, ~ NEo~~ ~+ ~ ~
N ~ 'C
U OO ~'~N~~ xNx N N O x N is U N ~
u~
x+ ~x~~ .:: xv~V.
O + O O ~ N M U iZ rj U N c.~ O ~ M r, Ov U z M ~ ~ oo U U x ~ QU U U~ U cYi " .N °.
~ ~~ ~ M ~; ~ ~,~o ~x x M a -= x x ~ MN~~cx x ~ ~~~.: x Nuu~c ~O M N_ M _N _~ x N .~
~.~~Nx~~~ .~ ~UN~.~ ~ uxx o0 U7 M .~ N U ~ O v0 d~ ... r ~ .. ~ti O U U .C D
~ n ~ M
n x ~ M M uj G C
O O
G! CJ
r 4! 0!
'L3 "a o ,L~° b~
ON ~
x ~ O .~
V ono O pp Q o0 O o Z o z o v~ U
'o Z n~ ~d'~ O
~M
N N O
V O U
"~, [~ p~ N
O
N O~
V
.. ..
N f..r O ~ ,~, M ~ d' x ~j II ~ II ~ II
V V V
~r ~r w .d m y '~ _~
X v .u ~ io V U
ate,. rte. ~ w ~
Q O o0 N
y v V
O O
N
O
W ~ ~ O pp O p~
V (r a 16 O
O O
'~r x O
x x O ~ M
x x ~ o o x M
x ' ~
O '~' ~ ~ d clvj d' M
z '~ ~ :~ ~ :~ ~ -~ z ' .., w- a x ~ ~ ~ ~ ~ ~ ~ U
cu N E N ~ N ~ ~ \
O O O N ~
~ tn ~ tn d, ~ d' ~ d' ~ ~ d~
~ O O O ~ O
o " N " N _~ , ' 'd' N ~ ~ U
cn O '~ ~ ~ p "~~ ~ "~~ cn '~
~
_~ . . ~ .fl ~ \ ~ o .
~, \~. ~ o ~ x\ x ~
o x \ x \ N~
x\ ~ ~ o .~ 0 _ ~ a~ O a~ ~ ~ v M ~ V U m x o ~ x~ ~a ~
M
o .~ . ~~ ~ ~ x ~ U U o z n Zzo cn Uo cn o cn z o c U ,-~, ~ ~, ~ ~. ~ ~.
~
,'.fl3 0 ~ 0 3 ~ -H ~ U ~ ~ U ~ ~ U H ~ ,.., 0 -H -H W 0 ~
U E-~
~a U E-H ..fl ~ a ~ a~
~ U E E E
2~8'~~84 ASSESSMENT OF BEHAVIOUR AND MORTALITY IN MICE.
The assessment of normal behaviour in mice was carned out following S.
Irwin's method (Psychopharmacologia, 13, 222 [1968]). This method allows alterations in some behavioural, neurophysiologic and neurovegetative parameters to be detected, which are directly observable by the researcher.
The study was conducted using male Crl:(CD-1)(ICR)BR mice (Charles River-Italy) weighing 22-25 g, following oral administration of the compounds suspended in carboxymethylcellulose (0.5% by weight in H20) to groups of 4 animals/dose.
The animals were continously kept under observation for five hours following treatment and twice a day in the subsequent five days. Mortality was also observed during the overall test period.
Assessment of behaviour and mortalit3r in mice.
Compound ose Symptoms Mortality ST 722 1000 salivation,diarrhoea O/4 ./.
,$ 208'~08~
IMMUNOTOgICOLOGICAL STUDIES
Some immunotoxicological results after oral ST 722 administration in mice are described hereinafter:
Test 1: Evaluation of the "in vitro-es vivo" effect of repeated oral administrations of ST 722 on the primary antibody produc-tion (Jerne test) in the spleen of SRBC (Sheep Red Blood Cells) immunized mice.
Experimental procedure Male BFI mice (C. River) aged 8 weeks (6 animals each group) were utilized.
The substance (ST 722) was administered per os at the dose of 100 mg/kg/day from day -2 through day +2 (immunization at day 0).
The animals were immunized by intraperitoneal route with a con-centration of 1.0x108 cells/mouse in 0.2 ml of sterile saline.
Five days later, spleens to be submitted to teasing process were removed from the animals sacrificed by cervical dislocation.
After standardization at l.OxlO~ cells/ml, the splenocytes (0.1 ml) were mixed with warm agar-Hank's (2 ml) and 10% SRBC in PBS
(0.2 ml) and seeded in Petri dishes (samples tested in triplicates) and incubated at 37°C for 60 min.
After addition of complement (2 ml of guinea pig serum diluted 1:10 2 5 in Tris buffer), samples were further incubated at 37°C for 30 min.
To block the haemolysis reaction, the Petri dishes were cooled at 4°C
,087084 and the haemolysis plaques were counted.
The antibody response to SRBC is expressed as number of plaque forming cells (PFC) per 1.0x106 splenocytes as well as per spleen.
Results The results indicated that the repeated (5 consecutive days) oral administrations of ST 722 did not cause a statistically significant modification in PFC number after the antigenic challenge (Table 1).
These data exclude the existence of an immunotoxic effect on the antibody-producer B lymphocytes.
The weight of the lymphoid organs (spleen and thymus) did not show values relating to a toxic effect as well (Tab. 1).
Table 1 Primary antibody production (Jerne test). Evaluation of the number of PFC (x~+S.E.) in the spleen of mice immunized with SRBC and treated per os with ST 722 at the dose of 100 mg/kg/day from day -2 through day +2 (immunization at day 0).
Body Spleen Thymus PFC/ 106 PFC/
Treatment weight weight weight cells spleen (g1 (mg) (mg) Control 25.33 95.50 64.00 20232 34228 10.38 3.19 1.51 5064 ST ?22 25.12 94.33 59.50 26134 44440 0.77 4.12 3.62 6087 ~~s7o~4 Test 2: Evaluation of the effect of repeated oral administrations of 8T 722 on the weight of marine lymphoid organs (spleen and thymus).
Eacperimental procedure Male BFI mice (C. River) aged 7 weeks (7-8 animals each group) were orally treated with the substance ST 722 at the dose of 100 mg/kg/day for 7 consecutive days. Twenty-four hours after the last administration, the animals were sacrificed, the organs removed and weighed.
Results The performed treatment did not provoke any immunotoxic effect on the parameters examined (Table 2).
Table 2 Weight (xtS.E.) of marine lymphoid organs after repeated treatment oral of the animals with the substance ST 722 (100 mg/kg/day for 7 consecutive days).
Treatment Body weights Spleen weights Thymus weights (g) (mg) (mg) Control 24.000.68 79.633.31 51.882.72 ST 722 22.740.37 77.882.38 52.883.20 a = mean value (x-+E.S.) of 7-8 samples.
208'084 Test 3: Evaluation of the effect of repeated oral administrations of ST 722 on the body, spleen and thymus weight, and on the splenocyte concentration In mice.
Experimental procedure Male B~F1 mice (C. River) aged 10 weeks (5 animals each group) were orally treated with the substance ST 722 at the dose of 100 mg/kg/day for 5 consecutive days. Twenty-four hours after the last administration, the animals were sacrificed, the organs removed and IO weighed, and the splenocyte number determined.
Results The results, reported in Table 3, showed a lack of specific im-munotoxic effects on the considered parameters following the scheduled ST 722 treatment.
Table 3 Weight of lymphoid organs and spleen concentration after repeated oral treatments of mice with the substance ST 722 (100 mg/kg/day for 5 consecutive days).
Treatment Body weights Splenoc. numberb Spleen weights Thymus weights (g) (mg) (x10-(mg) Control 27.700.48 75.752.36 4I.75f3.59 7.90 ST 722 26.500.53 73.253.84 38.803.01 7.85 a = mean value (x_+S.E.) of 5 samples.
b = value from 5 pooled samples.
Test 4: Evaluation of the effect of repeated oral administrations of ST ?22 on the peritoneal macrophage number in mice.
Experimental procedure Male B6D2Fi mice (C. River) aged 10 weeks (6 animals each group) were orally treated with the substance ST 722 at the dose of 100 mg/kg/day for 5 consecutive days. Twenty-four hours after the last administration, the animals were sacrificed, the peritoneal exudate cells (PEC ) collected and the macrophage number determined.
Results No toxic effect has been observed in PEC macrophage population; on the contrary, we measured an increase of about 60% in the peritoneal macrophages number of mice treated with the substance ST 722 (Table 4).
Table 4 Peritoneal macrophage (Mrs) number in mice treated with ST
?22 (100 mg/kg/day for 5 consecutive days).
Treatment Body weightPEC/mouseb PEC Mmb PEC Mm/mouseb a (X1O~6) (%) (X1O-s) Control 28.070.63 2.14 53 1.13 2 5 ST 722 28.131.30 2.86 63 1.80 a = mean value (~S.E.) of 6 animals.
b = Value from 6 pooled samples.
Evaluation of the Minimal Inhibitory Concentration (MIC) of 16 new substances for yeast and yeast-like strains.
Experimental procedure The following strains were used (the number of strains is in brack-ets):
Candida (13); Criptococcus (2); Saccharomyces (I); Torulopsis (I).
The tested substances were: ST 712, ST 722, ST 982, ST 983, ST
1000, ST 1001, ST 1032, ST 1033, ST 1034, ST 1036, ST 1037, ST
1038, ST 1050, ST 1051, ST 1052, ST 1053.
Yeast Nitrogen Base supplemented with 0.15% asparagine and 1.0%
glucose (as carbon source) was the medium utilized in the assays.
This medium was buffered with 0.165 M 2-(N-morpholino) propane sulfonic acid (MOPS), a non-chelating buffer.
The test was performed following the standard microdilution procedure and the inoculum suggestions of Pfaller (PFALLER M., RINALDI M.G., GALGIANI J.N., BARTLETT M.S., BODY B.A., ESPINEL-INGROFF A., FROMTLING R.A., HALL G.S., HUGHES G.E., ODDS F.C.
and SUGAR A.M.,1990. Collaborative investigation of variables in 2 0 susceptibility testing of yeasts. Antimicrob. Agents Chemother. Sept.
34, 9: 1648-1654) with COOK's modifications (COOK R., Mc IN'I'YRE
K.A. and GALGIANI J.M.,1990. Effect of incubation temperature, inoculum size, and medium on agreement of macro-and microdilu tion broth susceptibility test, results for yeasts. Antimicrob. Agents 2 5 Chemother. Avg. 34, 8:1542-1545).
The inoculum was prepared from an overnight broth culture (a 48-hour culture only for Cryptococcus) in Sabouraud broth and ap-X08'7084 propriately diluted to yield a final suspension containing approximately 5.0x106 Colony Forming Units per mI (CFU/ml), when compared to the Mc Farland's standard control (BRAY W.E., Clinical Laboratory Methods, 5th Ed. C.V. MOSBY, St. Louis, Mo, 1957).
After further diluting ( 1:50), a 0.150-~,1 volume of such fungal suspensions and an equal volume of the substance solutions were distributed into each well of a microtiter plate (96 wells, round bottom). Such a procedure eventually allowed for an "in vitro"
antimycotic activity assay utilizing final fungal inocula of approximately 5.0x104 CFU/ml.
lNaC evaluation After incubating the microtiter plates for 48 hours at 35°C, the MIC
for each strain was determined, which is defined as the lowest concentration of the test substance where no visible fungal growth occurs.
N~'C evaluation The minimal fungicidal concentration was evaluated by spot transferring onto Petri dishes, containing Sabouraud agar, 0.01-ml volumes of all the samples showing no visible fungal growth.
After incubation for 48 hours at 35°C, the MFC was determined, which is defined as the lowest concentration of the test substance that does not allow growth of agar subcultures.
Results The MIC values, determined after incubating samples for 48 hours at 35°C, and illustrated in Table 1-6, are exactely equal to MFC values (data not shown), proving that these substances possess a lytic and not a simple antiproliferative activity against the tested strains.
26 ~~~~0~~
Table 1 Minimal Inhibitory Concentration (mcg/ml) of 5 Isovaleryl L-Carnitine esters for yeast-like fungi.
ST ST ST ST ST
Strains 10Q2 722 10.1710~i31001 Candida albicaris (562) n.d. 3.12 1.56 1,56 3.12 Candida albicans (A 54) n.d. 3.12 1.56 1.56 3.12 Cartdida albicans (ATCC 2091) n.d. 3.12 1.56 3.12 6.25 Candida albicans (Ca 2) n.d. 1.56 1.56 n.d. 3.12 Candida aibicans (PG) 25 3.12 3.12 3.12 6.25 Candida aIbicans (ISS 1) 25 1.56 3.12 1.56 12.5 2 Candida glabrata (ISS 1 ) n. d. 6.25 3.12 3.12 6.25 Candida guilItermondii (ISS 1) n.d. 6.25 6.25 6.25 6.25 Candida krusei (ISS 1) n.d. 3.12 1.56 3.12 6.25 Candida parapsilosis (ISS 1) n.d. 6.25 3.12 3.12 6.25 Candida pseudoLropicalis (EC n.d. 6.25 6.25 3.12 12.5 1) Candida tropicalis (5705) n.d. 3.12 3.12 3.12 6.25 Candida tropicalis (ISS 1) 12.5 3.12 3.12 3.12 12.5 Cryptococcus neoformans (4711) n.d. 1.56 0.78 0.78 1.56 Cryptococcus neoformans (ISS 50 3.12 1.56 1.56 3.12 1) Saccharomyces cereuisiae (ATCC 100 3.12 3.12 3.12 6.25 7752) Torulopsis candida (D.S.) n.d. 6.25 3.12 3.12 6.25 n.d. = not determined.
20~'~Qg~
Table 2 Mean MIC values (mcg/ml) of 5 Isovaleryl L-Carnitine esters for yeast-like fungi.
Compound Mean MIC values* Tested Resistant strains strains (MIC > 100) ST 1032 42.50 5 0 ST 722 3.76 17 0 ST 103? 2.80 17 0 ST 1033 2.70 17 0 ST 1001 6.24 17 0 * = Mean MIC values versus susceptible strains.
_. 28 ~o~~os~
Table 3 Minimal Inhibitory Concentration (mcg/ml) of 6 Undecyl L-Carnitine esters for yeast-like fungi.
Strains ST ST ST ST ST ST
Candida aIbicans (562) 12.5 1.56 1.56 n.d. n.d. n.d.
Candida, albicans (A 54) 12.5 1.56 1.56 6.25 > > 100 Candida, albicans (ATCC 2091) 12.5 1.56 1.56 n.d. n.d. n.d.
Candida albicans (Ca 2) 6.25 1.56 1.56 1.56 > > 100 Candida. albicans (PG) 12.5 3.12 3.12 n.d. n.d. n.d.
Candida. albicans (ISS 1) n.d. 1.56 1.56 3.12 n.d. n.d.
Candida, glabrata (ISS 1) n.d. 3.12 3.12 6.25 n.d. n.d.
Candida. guilIiermondii (ISS n.d. 6.25 6.25 6.25 n.d. n.d.
1) Candida krusei (ISS 1) n.d. 1.56 1.56 1.56 n.d. n.d.
2 Candida parapsiIosis (ISS 1) n.d. 6.25 6.25 6.25 n.d. n.d.
Candidapseudotropicalis (EC 12.5 6.25 6.25 n.d. n.d. n.d.
1) Candida tropicaIis (5705) 3.12 3.12 3.12 n.d. >100 >100 Candida tropicalis (ISS 1) n.d. 3.12 3.12 3.12 n.d. n.d.
Cryptococcus neojormans (4711 3.12 1.56 1.56 1.56 > > 100 ) 100 Cryptococcus neojormans (ISS n.d. 3.12 3.12 n.d. n.d. n.d.
1) Saccharomyces cereuisiae (ATCC 6.25 3.12 3.12 n.d. n.d. n.d.
7752) Torulopsis candida (D.S.) 12.5 3.12 3.12 6.25 >100 >100 n. d. = not determined.
20~'~084 Table 4 Mean MIC values (mcg/ml) of 6 Undecyl L- Carnitine esters for yeast-like fungi.
Compound Mean MIC values* Tested Resistant strains strains (MIC > 100) ST 712 9.37 10 0 ST 1034 3.03 17 0 ST 1036 2.84 17 0 ST 1000 4.21 10 0 ST 982 >100 5 5 ST 983 > 100 5 5 * = Mean MIC values versus susceptible strains.
30 208'~~084 Table 5 Minimal Inhibitory Concentration (mcg/ml) of 5 L-Carnitine esters for yeast-like fungi.
-ST ST ST ST ST
Strains 1038 1052 1051 1050 1x63 Candida aLbicans (562) 3.12 3.12 3.12 6.25 12.5 Candida albicarts (A 54) 3.12 n.d. n.d. n.d. n.d.
Candida albicarts (ATCC 2091) 3.12 n.d. n.d. n.d. n.d.
Candida atbicans (Ca 2) 1.56 1.56 1.56 3.12 3.12 Candida aibicarts (PG) 6.25 n.d. n.d. n.d, n.d.
Candida albicans (ISS 1) 6.25 n.d. n.d. n.d. n.d.
CandidagLabrata (ISS 1) 6.25 n.d. n.d. n.d. n.d.
Candida guiILiermondii (ISS 1) 6.25 n.d. n.d. n.d. n.d.
Candidu krusei (ISS 1) 3.12 3.12 3.12 3.12 3.12 Candida. parapsilosis (ISS 1) 6.25 n.d. n.d. n.d. n.d.
Candidu. pseudotropicaLis (EC 6.25 n.d. n.d. n.d. n.d.
1) Candida tropicalis (5705) 3.12 3.12 3.12 6.25 6.25 Candida tropicaLis (ISS 1) 3.12 n.d. n.d. n.d. n.d.
Cryptococcus neoformans (4711) 1.56 n.d. n.d. n.d. n.d.
Cryptococcus neoformans (ISS 3.12 n.d. n.d. n.d. n.d.
1) Saccharomyces cereuisiae (ATCC 6.25 3.12 3.12 3.12 3.12 7752) Torulopsis candida (D.S.) 6.25 n.d. n.d. n.d. n.d.
n.d. = not determined.
w..' 3' 2087084 Table 6 Mean MIC values (mcg/ml) of 5 L-Carnitine esters for yeast-like fungi.
Compound Mean MIC values* Tested Resistant strains strains (MIC > 100) ST 1038 4.40 17 0 ST 1052 2.80 5 0 ST 1051 2.80 5 0 ST 1050 4.37 5 0 ST 1053 5.62 5 0 * = Mean MIC values versus susceptible strains.
2(~~708~
Evaluation of Minimal Inhibitory Concentration (MIC) of 16 new substances for ~lamentous fungi.
Experimental procedure The following strains were used (the number of strains is in brack-ets):
Aspergillus (5); Fusarium (1); Mucor (1); Penicillium (1).
The tested substances were: ST 712, ST 722, ST 982, ST 983, ST
1000, ST 1001, ST 1032, ST 1033, ST 1034, ST 1036, ST 1037, ST
1038, ST 1050, ST 1051, ST 1052, ST 1053.
The assay medium was the same as the one used in the previous study. The conidia from 72-hour cultures in Sabouraud agar, col lected by washing with Sabouraud medium and Tween 80 (one drop of Tween per 10 ml of medium), were utilized as inoculum (5.0x104 CFU/ml).
The assay was performed using the same procedure as described for yeast-like fungi.
Also the evaluation of MIC and MFC was as reported previously.
2 0 Results The MIC values, reported in Tables 7-12, were exactly the same as the MFC values (data not shown), determined by a subculture tecni-que.
Table 7 Minimal Inhibitory Concentration (mcg/ml) of 5 Isovaleryl L-Carnitine esters for filamentous fungi.
ST ST ST ST ST
Strains 1032 722 103? lOCi3 1001 AspergiLLus ficmigatus (ATCC > 100 12.5 6.25 3.12 6.25 28212) Aspergillus fumigates ( 1 /A) n.d. 12.5 6.25 3.12 6.25 Aspergillus jumigatus (2/A) n.d. 12.5 6.25 3.12 6.25 ~~gd~~~~atus (C/ 1) n.d. 12.5 6.25 3.12 6.25 Aspergiltus niger (ATCC 16404)> 100 12.5 6.25 6.25 12.5 Mucor mucedo (ATCC 7941 ) > 100 50 12.5 6.25 > 100 Fusarium sp. (ISS 1) 100 6.25 3.12 3.12 12.5 Penicillium sp. ( 1302) 100 12.5 6.25 3.12 6.25 2 5 n. d. = not determined.
208'~t~84 Table 8 Mean MIC values (mcg/ml) of 5 Isovaleryl L- Carnitine esters for filamentous fungi.
Compound Mean MIC values* Tested Resistant strains strains (MIC > 100) ST 722 16.40 8 0 ST 103? 6.64 8 0 ST 1033 3.90 8 0 ST 1001 7.03 8 1 * = Mean MIC values versus susceptible strains.
208'~08~
-'~ 35 Table 9 Mean MIC values (mcg/ml) of 6 Undecyl L- Carnitine esters for filamentous fungi.
Strains ST ST ST ST ST ST
AspergiIius fumigates (ATCC 25 6.25 3.12 3.12 > > 100 28212) 100 Aspergillus fumigates (1/A) 25 6.25 6.25 n.d. n.d. n.d.
AspergiILus,fumigatus (2/A) 25 3.12 6.25 n.d. n.d. n.d.
AspergQius fumigates (C/1) 25 6.25 3.12 n.d. n.d. n.d.
Aspergil(us niger (ATCC 16404)50 6.25 3.12 3.12 >100 >100 Mucor mucedo (ATCC 7941) 50 12.5 6.25 6.25 > > 100 Fusarturrt sp. (ISS 1 ) n. d. 3. 3.12 3.12 > > 100 i 100 PenicilLium sp. ( 1302) n.d. 3.12 3.12 3.12 > > 100 n.d. = not determined.
Table 10 Mean MIC values (mcg/ml) of 6 Undecyl L-Carnitine esters for filamentous fungi.
Compound Mean MIC values* Tested Resistant strains strains (MIC > 100) ST 712 30.00 6 1 ST 1034 5.85 8 0 ST 1036 4.29 8 0 ST 1000 3.76 5 0 ST 982 >100 5 5 ST 983 >100 5 5 * = Mean MIC values versus susceptible strains.
208'~08~
Table 11 Minimal Inhibitory Concentration (mcg/ml) of 5 L-Carnitine esters for filamentous fungi.
ST ST ST ST ST
Strains 10~i8 1052 1050 1061 1053 Aspergiltus fumigates (ATCC 12.5 3.12 6.25 3.12 6.25 28212) Aspergillus fumigates ( 1 /A) 12.5 n.d. n.d. n.d. n.d.
AspergiIlus fi.~migatus (2/A) 12.5 n.d. n.d. n.d. n.d.
Aspergillus fumigates (C/ 1) 6.25 n.d. n.d. n.d. n.d.
Aspergiilus niger (ATCC 16404) 12.5 3.12 6.25 6.25 3.12 Mucor mucedo (ATCC 7941) 25 6.25 12.5 6.25 12.5 Fusarium sp. (ISS 1) 6.25 6.25 6.25 6.25 6.25 PenicfIlium sp. ( 1302) 12.5 3.12 3.12 3.12 3.12 2 5 n.d. = not determined.
Table 12 Mean MIC values (mcg/ml) of 5 L-Carnitine esters for filamentous fungi.
Compound Mean MIC values* Tested Resistant strains strains (MIC > 100) ST 1038 12.50 8 0 ST 1052 4.37 5 0 ST 1050 6.85 5 0 ST 1051 6.87 5 0 ST 1053 6.24 5 O
* = Mean MIC values versus susceptible strains.
Evaluation of Minimal Inhibitory Concentration (MIC) of ? new substances for dermatophytic fungi.
Experimental procedure The following strains were used: Trichophyton menthagrophytes ATCC 9533, Trichophyton rubrum IHEM 4274, Microsporum canis IHEM 3522, Epydermophyton floccosum IHEM 3495.
The tested substances were: ST 722, ST 1033. ST 1037, ST 1050, ST 1051, ST 1052, ST 1053.
The assay was performed following the same procedure described for the yeasts, by using 7-day fungi cultures grown at 30°C in Potato Dextrose agar, and harvested with Sabouraud broth and lween 80 (0.5%).
After washing with Yeast Nitrogen Base, supplemented with asparagine and glucose ( as carbon source), the fungal suspension was fragmented using a tissue grinder until the largest clumps or ag gregates were undetectable within the grinder. This fungal suspen sion was then appropriately diluted in YNB to yield a concentration of 2.0x105 infective particles/ml (small mycelium fragments, micro-and macroaleuriospores).
Volumes of 100 ~.l both of the fungal suspensions and substance solutions, two-fold serially diluted in assay medium, were distributed into each well of a microtiter plate (96 wells, round bottom), which was incubated at 35°C for 96 hours.
The MIC values, substantially corresponding to the MFC values (data not shown), are reported in Table 13-14.
.. . 39 Table 13 Minimal Inhibitory Concentration (mcg/ml) of 7 new substances for dermatophytic fungi.
Strains ST ST ST ST ST ST ST
103;1 Epidermoph~ton floccosum (IHEM 50 25 25 25 50 25 50 3495) Microsporum cants (IHEM 3522) 25 12.5 6.2512.512.5 6.25 6.25 Trichophyton rubrum (IHEM 4274) 12.56.25 6.256.256.25 6.25 6.25 Trichophyton menthugrophites (ATCC25 12.5 12.512.512.5 6.25 9533) 12.5 IS
Table 14 Mean MIC values (mcg/ml) of ? new substances for dermatophytic fungi.
Compound Mean MIC values* Tested Resistant strains strains (MIC > 100) ST 722 28.12 4 0 2 ST 1037 14.06 4 0 ST 1033 12.50 4 0 ST 1052 12.50 4 0 ST 1050 20.31 4 0 ST 1051 14.06 4 0 3 ST 1053 14.06 4 0 * = Mean MIC values versus susceptible strains.
2(18708 Evaluation of the protective effects of ST ?22 in an experimental subcutaneous infection with Candida aibicares in mice.
Experimental procedure Male CD ~ outbred mice (IFFA Credo) aged 8 weeks were used (4 animals per group).
Bacterial strain A pathogenic strain of Candida was used, namely C. albicans ISS 1.
The MIC of ST 722 against this strain was 1.56 mcg/ml, whereas the MIC of Miconazole, a reference compound, was not determined, although the data available from the literature indicate MIC values ranging from 0.5 to 10 mcg/ml.
Compounds The infected animals were treated with ST 722 dissolved in saline, and Miconazole diluted in saline from a stock solution containing 1%
Dimethyl Formamide.
Infective model From an overnight broth culture of C. albicans in Sabouraud broth, a fungal suspension was prepared in sterile saline containing 5.0x105 cells/ml. An inoculum of 0.5 ml of this suspension was injected subcutaneously into the abdominal wall of each animal.
2(187$4 The compounds were then administered by subcutaneous infection in the same area of the fungal challenge at the dose of 50 mcg (in 0.2 ml of saline) immediately after the inoculum and following 48 and 96 hours (150 total mcg per animal).
Then, 48 hours following the last treatment (6 days after the chal-lenge with Candida), the animals were sacrificed, and the abdominal wall as well as the peritoneum were dissected out.
The excised tissues were then homogenized in 5 ml of sterile saline with a Potter-Elveh~em tissue grinder. The resulting suspensions, appropriately diluted, where plated onto Petri dishes containing a selective agar medium (BIGGY agar), which allows to easily detect the yeast Colony Forming Units (CFU/ml).
Evaluation of results The number of colonies scored in a series of dilutions for each single sample consents to calculate the number of yeast cells present in the infected tissue sample as follows:
E C;
Number of yeast cells =
2 0 E N;Z;
Where Z; is the number of dilutions performed, Ni is the number of plates prepared for each dilution, and C; is the total number of yeast cells scored in each dilution.
Results The results reported in Table 1 show that ST 722, administered as described above, substantially inhibits the infection with Candida, inducing the disappearance of Candida cells from the abdomen of treated animals (3 sterile samples out of 4). Similar experimental results were attained with Miconazole.
Table 1 Effect of ST 722 and Miconazole (reference compound) in an experimental subcutaneous infection with Candida albicans in mice.
Treatment Sample CFU/ mouse Control 1-4 1.19x 104 (*) ST 722 1 sterile 2 sterile 3 sterile 4 1.36x 102 Miconazole I sterile 2 sterile 3 3.60x 101 4 8.10x101 (*) = Mean CFU value of 4 control samples.
Evaluation of the protective effect of ST ?22 in a systemic ez-perimental infection with Candida atbicans in mice.
Ezperimental procedure Animals Male CDi mice (C. River) aged 6 or 13 weeks were used (12-15 animals per group).
Yeast strain The pathogenic strain of Candida utilized, i.e. C. albicans PG, was able, when inoculated intravenously, to cause multiple renal lesions and systemic dissemination, provoking death of the animals within 40 days from the challenge. The compound ST 722 exibits against this Candida strain a value of MIC and MFC equal to 3.12 mcg/ml.
Inoculum preparation A broth culture in Sabouraud broth is prepared from a 48-hour agar slant culture.
After incubation for 48 hours at 37°C, the broth culture is first washed 3 times with sterile saline, then adjusted to a concentration of 2.0x106 cells/ml. Volumes of 0.25 ml of this suspension are i.v.
injected into the animals, with a resulting infective dose approximately corresponding to DLioo.
~.. 44 Treatment ST 722 was administered per os following two different protocols:
I ) 100 mg/kg administered at +2, +12. +24, +36 and +48 hours (i.e. 5 administrations in two days) with respect to the challenge.
II) 100 mg/kg administered twice daily on 6 consecutive days (i.e.
12 adimistrations) starting from day -2 to day +3 with respect to the day of inoculation (day 0).
L~aluation criteria After the challenge, the animals were followed up for 60 days, and the percent mortality as well as the mean survival time (MST) were evaluated. The statistical significance of the results was evaluated by means of Fisher "exact test" and Mann-Withney "U" test, respec-tively.
Results The protective effect of ST 722, only in terms of MST prolongation, was confirmed in both protocol I and II. In fact, also in protocol II
the percent mortality of mice was completely unaffected. although the number of administrations was raised and the ST 722 treatment was started two days prior to the challenge (Table 2 and 3 ).
Table 2 Protective effect of ST 722 in mice experimentally infected with a C. aIbicans pathogenic strain.
Treatment Dead /Total % Mortality MST (days)a Control 13/15 86.6 22 (15-3D) ST 722b 10/ I4 71.4 3? (25- ~60)~
a = Mean survival time (range of variation is in brackets). The animals were followed up for 60 consecutive days after challenge (day 0).
b = The substance was administered according to protocol I.
~ = p50.05 (Mann-Withney "U" test).
Table 3 Protective effect of ST 722 in mice experimentally infected with a C. aibicans pathogenic strain.
Treatment Dead /Total % Mortality MST (days)a Control 10/ 12 83.3 26 (22-39) ST ?22b 10/ 14 71.4 44 (32- >_60)~
a = Mean survival time (range of variation is in brackets). The animals were followed up for 60 consecutive days after challenge (day 0).
b = The substance was administered according to protocol II.
~ = p<_0.05 (Ma.nn-Withney "U" test).
1) Candida tropicaIis (5705) 3.12 3.12 3.12 n.d. >100 >100 Candida tropicalis (ISS 1) n.d. 3.12 3.12 3.12 n.d. n.d.
Cryptococcus neojormans (4711 3.12 1.56 1.56 1.56 > > 100 ) 100 Cryptococcus neojormans (ISS n.d. 3.12 3.12 n.d. n.d. n.d.
1) Saccharomyces cereuisiae (ATCC 6.25 3.12 3.12 n.d. n.d. n.d.
7752) Torulopsis candida (D.S.) 12.5 3.12 3.12 6.25 >100 >100 n. d. = not determined.
20~'~084 Table 4 Mean MIC values (mcg/ml) of 6 Undecyl L- Carnitine esters for yeast-like fungi.
Compound Mean MIC values* Tested Resistant strains strains (MIC > 100) ST 712 9.37 10 0 ST 1034 3.03 17 0 ST 1036 2.84 17 0 ST 1000 4.21 10 0 ST 982 >100 5 5 ST 983 > 100 5 5 * = Mean MIC values versus susceptible strains.
30 208'~~084 Table 5 Minimal Inhibitory Concentration (mcg/ml) of 5 L-Carnitine esters for yeast-like fungi.
-ST ST ST ST ST
Strains 1038 1052 1051 1050 1x63 Candida aLbicans (562) 3.12 3.12 3.12 6.25 12.5 Candida albicarts (A 54) 3.12 n.d. n.d. n.d. n.d.
Candida albicarts (ATCC 2091) 3.12 n.d. n.d. n.d. n.d.
Candida atbicans (Ca 2) 1.56 1.56 1.56 3.12 3.12 Candida aibicarts (PG) 6.25 n.d. n.d. n.d, n.d.
Candida albicans (ISS 1) 6.25 n.d. n.d. n.d. n.d.
CandidagLabrata (ISS 1) 6.25 n.d. n.d. n.d. n.d.
Candida guiILiermondii (ISS 1) 6.25 n.d. n.d. n.d. n.d.
Candidu krusei (ISS 1) 3.12 3.12 3.12 3.12 3.12 Candida. parapsilosis (ISS 1) 6.25 n.d. n.d. n.d. n.d.
Candidu. pseudotropicaLis (EC 6.25 n.d. n.d. n.d. n.d.
1) Candida tropicalis (5705) 3.12 3.12 3.12 6.25 6.25 Candida tropicaLis (ISS 1) 3.12 n.d. n.d. n.d. n.d.
Cryptococcus neoformans (4711) 1.56 n.d. n.d. n.d. n.d.
Cryptococcus neoformans (ISS 3.12 n.d. n.d. n.d. n.d.
1) Saccharomyces cereuisiae (ATCC 6.25 3.12 3.12 3.12 3.12 7752) Torulopsis candida (D.S.) 6.25 n.d. n.d. n.d. n.d.
n.d. = not determined.
w..' 3' 2087084 Table 6 Mean MIC values (mcg/ml) of 5 L-Carnitine esters for yeast-like fungi.
Compound Mean MIC values* Tested Resistant strains strains (MIC > 100) ST 1038 4.40 17 0 ST 1052 2.80 5 0 ST 1051 2.80 5 0 ST 1050 4.37 5 0 ST 1053 5.62 5 0 * = Mean MIC values versus susceptible strains.
2(~~708~
Evaluation of Minimal Inhibitory Concentration (MIC) of 16 new substances for ~lamentous fungi.
Experimental procedure The following strains were used (the number of strains is in brack-ets):
Aspergillus (5); Fusarium (1); Mucor (1); Penicillium (1).
The tested substances were: ST 712, ST 722, ST 982, ST 983, ST
1000, ST 1001, ST 1032, ST 1033, ST 1034, ST 1036, ST 1037, ST
1038, ST 1050, ST 1051, ST 1052, ST 1053.
The assay medium was the same as the one used in the previous study. The conidia from 72-hour cultures in Sabouraud agar, col lected by washing with Sabouraud medium and Tween 80 (one drop of Tween per 10 ml of medium), were utilized as inoculum (5.0x104 CFU/ml).
The assay was performed using the same procedure as described for yeast-like fungi.
Also the evaluation of MIC and MFC was as reported previously.
2 0 Results The MIC values, reported in Tables 7-12, were exactly the same as the MFC values (data not shown), determined by a subculture tecni-que.
Table 7 Minimal Inhibitory Concentration (mcg/ml) of 5 Isovaleryl L-Carnitine esters for filamentous fungi.
ST ST ST ST ST
Strains 1032 722 103? lOCi3 1001 AspergiLLus ficmigatus (ATCC > 100 12.5 6.25 3.12 6.25 28212) Aspergillus fumigates ( 1 /A) n.d. 12.5 6.25 3.12 6.25 Aspergillus jumigatus (2/A) n.d. 12.5 6.25 3.12 6.25 ~~gd~~~~atus (C/ 1) n.d. 12.5 6.25 3.12 6.25 Aspergiltus niger (ATCC 16404)> 100 12.5 6.25 6.25 12.5 Mucor mucedo (ATCC 7941 ) > 100 50 12.5 6.25 > 100 Fusarium sp. (ISS 1) 100 6.25 3.12 3.12 12.5 Penicillium sp. ( 1302) 100 12.5 6.25 3.12 6.25 2 5 n. d. = not determined.
208'~t~84 Table 8 Mean MIC values (mcg/ml) of 5 Isovaleryl L- Carnitine esters for filamentous fungi.
Compound Mean MIC values* Tested Resistant strains strains (MIC > 100) ST 722 16.40 8 0 ST 103? 6.64 8 0 ST 1033 3.90 8 0 ST 1001 7.03 8 1 * = Mean MIC values versus susceptible strains.
208'~08~
-'~ 35 Table 9 Mean MIC values (mcg/ml) of 6 Undecyl L- Carnitine esters for filamentous fungi.
Strains ST ST ST ST ST ST
AspergiIius fumigates (ATCC 25 6.25 3.12 3.12 > > 100 28212) 100 Aspergillus fumigates (1/A) 25 6.25 6.25 n.d. n.d. n.d.
AspergiILus,fumigatus (2/A) 25 3.12 6.25 n.d. n.d. n.d.
AspergQius fumigates (C/1) 25 6.25 3.12 n.d. n.d. n.d.
Aspergil(us niger (ATCC 16404)50 6.25 3.12 3.12 >100 >100 Mucor mucedo (ATCC 7941) 50 12.5 6.25 6.25 > > 100 Fusarturrt sp. (ISS 1 ) n. d. 3. 3.12 3.12 > > 100 i 100 PenicilLium sp. ( 1302) n.d. 3.12 3.12 3.12 > > 100 n.d. = not determined.
Table 10 Mean MIC values (mcg/ml) of 6 Undecyl L-Carnitine esters for filamentous fungi.
Compound Mean MIC values* Tested Resistant strains strains (MIC > 100) ST 712 30.00 6 1 ST 1034 5.85 8 0 ST 1036 4.29 8 0 ST 1000 3.76 5 0 ST 982 >100 5 5 ST 983 >100 5 5 * = Mean MIC values versus susceptible strains.
208'~08~
Table 11 Minimal Inhibitory Concentration (mcg/ml) of 5 L-Carnitine esters for filamentous fungi.
ST ST ST ST ST
Strains 10~i8 1052 1050 1061 1053 Aspergiltus fumigates (ATCC 12.5 3.12 6.25 3.12 6.25 28212) Aspergillus fumigates ( 1 /A) 12.5 n.d. n.d. n.d. n.d.
AspergiIlus fi.~migatus (2/A) 12.5 n.d. n.d. n.d. n.d.
Aspergillus fumigates (C/ 1) 6.25 n.d. n.d. n.d. n.d.
Aspergiilus niger (ATCC 16404) 12.5 3.12 6.25 6.25 3.12 Mucor mucedo (ATCC 7941) 25 6.25 12.5 6.25 12.5 Fusarium sp. (ISS 1) 6.25 6.25 6.25 6.25 6.25 PenicfIlium sp. ( 1302) 12.5 3.12 3.12 3.12 3.12 2 5 n.d. = not determined.
Table 12 Mean MIC values (mcg/ml) of 5 L-Carnitine esters for filamentous fungi.
Compound Mean MIC values* Tested Resistant strains strains (MIC > 100) ST 1038 12.50 8 0 ST 1052 4.37 5 0 ST 1050 6.85 5 0 ST 1051 6.87 5 0 ST 1053 6.24 5 O
* = Mean MIC values versus susceptible strains.
Evaluation of Minimal Inhibitory Concentration (MIC) of ? new substances for dermatophytic fungi.
Experimental procedure The following strains were used: Trichophyton menthagrophytes ATCC 9533, Trichophyton rubrum IHEM 4274, Microsporum canis IHEM 3522, Epydermophyton floccosum IHEM 3495.
The tested substances were: ST 722, ST 1033. ST 1037, ST 1050, ST 1051, ST 1052, ST 1053.
The assay was performed following the same procedure described for the yeasts, by using 7-day fungi cultures grown at 30°C in Potato Dextrose agar, and harvested with Sabouraud broth and lween 80 (0.5%).
After washing with Yeast Nitrogen Base, supplemented with asparagine and glucose ( as carbon source), the fungal suspension was fragmented using a tissue grinder until the largest clumps or ag gregates were undetectable within the grinder. This fungal suspen sion was then appropriately diluted in YNB to yield a concentration of 2.0x105 infective particles/ml (small mycelium fragments, micro-and macroaleuriospores).
Volumes of 100 ~.l both of the fungal suspensions and substance solutions, two-fold serially diluted in assay medium, were distributed into each well of a microtiter plate (96 wells, round bottom), which was incubated at 35°C for 96 hours.
The MIC values, substantially corresponding to the MFC values (data not shown), are reported in Table 13-14.
.. . 39 Table 13 Minimal Inhibitory Concentration (mcg/ml) of 7 new substances for dermatophytic fungi.
Strains ST ST ST ST ST ST ST
103;1 Epidermoph~ton floccosum (IHEM 50 25 25 25 50 25 50 3495) Microsporum cants (IHEM 3522) 25 12.5 6.2512.512.5 6.25 6.25 Trichophyton rubrum (IHEM 4274) 12.56.25 6.256.256.25 6.25 6.25 Trichophyton menthugrophites (ATCC25 12.5 12.512.512.5 6.25 9533) 12.5 IS
Table 14 Mean MIC values (mcg/ml) of ? new substances for dermatophytic fungi.
Compound Mean MIC values* Tested Resistant strains strains (MIC > 100) ST 722 28.12 4 0 2 ST 1037 14.06 4 0 ST 1033 12.50 4 0 ST 1052 12.50 4 0 ST 1050 20.31 4 0 ST 1051 14.06 4 0 3 ST 1053 14.06 4 0 * = Mean MIC values versus susceptible strains.
2(18708 Evaluation of the protective effects of ST ?22 in an experimental subcutaneous infection with Candida aibicares in mice.
Experimental procedure Male CD ~ outbred mice (IFFA Credo) aged 8 weeks were used (4 animals per group).
Bacterial strain A pathogenic strain of Candida was used, namely C. albicans ISS 1.
The MIC of ST 722 against this strain was 1.56 mcg/ml, whereas the MIC of Miconazole, a reference compound, was not determined, although the data available from the literature indicate MIC values ranging from 0.5 to 10 mcg/ml.
Compounds The infected animals were treated with ST 722 dissolved in saline, and Miconazole diluted in saline from a stock solution containing 1%
Dimethyl Formamide.
Infective model From an overnight broth culture of C. albicans in Sabouraud broth, a fungal suspension was prepared in sterile saline containing 5.0x105 cells/ml. An inoculum of 0.5 ml of this suspension was injected subcutaneously into the abdominal wall of each animal.
2(187$4 The compounds were then administered by subcutaneous infection in the same area of the fungal challenge at the dose of 50 mcg (in 0.2 ml of saline) immediately after the inoculum and following 48 and 96 hours (150 total mcg per animal).
Then, 48 hours following the last treatment (6 days after the chal-lenge with Candida), the animals were sacrificed, and the abdominal wall as well as the peritoneum were dissected out.
The excised tissues were then homogenized in 5 ml of sterile saline with a Potter-Elveh~em tissue grinder. The resulting suspensions, appropriately diluted, where plated onto Petri dishes containing a selective agar medium (BIGGY agar), which allows to easily detect the yeast Colony Forming Units (CFU/ml).
Evaluation of results The number of colonies scored in a series of dilutions for each single sample consents to calculate the number of yeast cells present in the infected tissue sample as follows:
E C;
Number of yeast cells =
2 0 E N;Z;
Where Z; is the number of dilutions performed, Ni is the number of plates prepared for each dilution, and C; is the total number of yeast cells scored in each dilution.
Results The results reported in Table 1 show that ST 722, administered as described above, substantially inhibits the infection with Candida, inducing the disappearance of Candida cells from the abdomen of treated animals (3 sterile samples out of 4). Similar experimental results were attained with Miconazole.
Table 1 Effect of ST 722 and Miconazole (reference compound) in an experimental subcutaneous infection with Candida albicans in mice.
Treatment Sample CFU/ mouse Control 1-4 1.19x 104 (*) ST 722 1 sterile 2 sterile 3 sterile 4 1.36x 102 Miconazole I sterile 2 sterile 3 3.60x 101 4 8.10x101 (*) = Mean CFU value of 4 control samples.
Evaluation of the protective effect of ST ?22 in a systemic ez-perimental infection with Candida atbicans in mice.
Ezperimental procedure Animals Male CDi mice (C. River) aged 6 or 13 weeks were used (12-15 animals per group).
Yeast strain The pathogenic strain of Candida utilized, i.e. C. albicans PG, was able, when inoculated intravenously, to cause multiple renal lesions and systemic dissemination, provoking death of the animals within 40 days from the challenge. The compound ST 722 exibits against this Candida strain a value of MIC and MFC equal to 3.12 mcg/ml.
Inoculum preparation A broth culture in Sabouraud broth is prepared from a 48-hour agar slant culture.
After incubation for 48 hours at 37°C, the broth culture is first washed 3 times with sterile saline, then adjusted to a concentration of 2.0x106 cells/ml. Volumes of 0.25 ml of this suspension are i.v.
injected into the animals, with a resulting infective dose approximately corresponding to DLioo.
~.. 44 Treatment ST 722 was administered per os following two different protocols:
I ) 100 mg/kg administered at +2, +12. +24, +36 and +48 hours (i.e. 5 administrations in two days) with respect to the challenge.
II) 100 mg/kg administered twice daily on 6 consecutive days (i.e.
12 adimistrations) starting from day -2 to day +3 with respect to the day of inoculation (day 0).
L~aluation criteria After the challenge, the animals were followed up for 60 days, and the percent mortality as well as the mean survival time (MST) were evaluated. The statistical significance of the results was evaluated by means of Fisher "exact test" and Mann-Withney "U" test, respec-tively.
Results The protective effect of ST 722, only in terms of MST prolongation, was confirmed in both protocol I and II. In fact, also in protocol II
the percent mortality of mice was completely unaffected. although the number of administrations was raised and the ST 722 treatment was started two days prior to the challenge (Table 2 and 3 ).
Table 2 Protective effect of ST 722 in mice experimentally infected with a C. aIbicans pathogenic strain.
Treatment Dead /Total % Mortality MST (days)a Control 13/15 86.6 22 (15-3D) ST 722b 10/ I4 71.4 3? (25- ~60)~
a = Mean survival time (range of variation is in brackets). The animals were followed up for 60 consecutive days after challenge (day 0).
b = The substance was administered according to protocol I.
~ = p50.05 (Mann-Withney "U" test).
Table 3 Protective effect of ST 722 in mice experimentally infected with a C. aibicans pathogenic strain.
Treatment Dead /Total % Mortality MST (days)a Control 10/ 12 83.3 26 (22-39) ST ?22b 10/ 14 71.4 44 (32- >_60)~
a = Mean survival time (range of variation is in brackets). The animals were followed up for 60 consecutive days after challenge (day 0).
b = The substance was administered according to protocol II.
~ = p<_0.05 (Ma.nn-Withney "U" test).
Claims (13)
1. Esters of acyl L-carnitines of general formula wherein:
R is a straight or branched acyl group having 2 - 16 carbon atoms, n is an integer comprised between 7 and 15, and X- is the anion of a pharmacologically acceptable acid.
R is a straight or branched acyl group having 2 - 16 carbon atoms, n is an integer comprised between 7 and 15, and X- is the anion of a pharmacologically acceptable acid.
2. The esters of claim 1 wherein R is isobutyryl or isovaleryl.
3. The esters of claim 1 wherein n is 10.
4. The esters of any one of claims 1 to 3 wherein X- is selected from:
chloride; bromide; iodide; aspartate; citrate; tartrate; phosphate; fumarate;
glycerophosphate; glucosephosphate; lactate; maleate; orotate; oxalate;
sulphate; trichloroacetate; trifluoroacetate and methansulphonate.
chloride; bromide; iodide; aspartate; citrate; tartrate; phosphate; fumarate;
glycerophosphate; glucosephosphate; lactate; maleate; orotate; oxalate;
sulphate; trichloroacetate; trifluoroacetate and methansulphonate.
5. The esters according to claim 4 wherein X- is selected from: acid asparatate; acid citrate; acid phosphate; acid fumarate; acid maleate; acid oxalate and acid sulphate.
6. Isovaleryl L-carnitine undecyl ester chloride.
7. Isobutyryl L-carnitine undecyl ester chloride.
8. An orally or parenterally administrable or topically applicable pharmaceutical composition comprising an ester of any one of claims 1 to 7 as active ingredient and a pharmaceutically acceptable excipient.
9. The pharmaceutical composition of claim 8 having antimycotic activity, comprising an amount of an ester of any one of claims 1 to 7, effective for inducing an antimycotic effect.
10. The pharmaceutical composition of claim 9 for trepang infections sustained by yeast-like fungi.
11. The pharmaceutical composition of claim 10 for treating infections sustained by Candida albicans, Candida tropicalis, Candida pseudotropicalis, Torulopsis candida, Saccharomices cerevisiae and Cryptococcus neoformans.
12. The pharmaceutical composition of claim 9 for treating infections sustained by filamentous fungi.
13. The pharmaceutical composition of claim 12 for treating infections sustained by Aspergillus fumigalus, Aspergillus niger and Mucor mucedo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM92A000028 | 1992-01-16 | ||
| ITRM920028A IT1254136B (en) | 1992-01-16 | 1992-01-16 | ACIL CARNITINE ESTERS WITH LONG CHAIN ALIPHATIC ALCOHOLS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, WITH ANTI-Fungal activity. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2087084A1 CA2087084A1 (en) | 1993-07-17 |
| CA2087084C true CA2087084C (en) | 2003-12-23 |
Family
ID=11400574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002087084A Expired - Fee Related CA2087084C (en) | 1992-01-16 | 1993-01-11 | Esters of acyl carnitines with long-chain aliphatic alcohols and pharmaceutical compositions containing same having antimycotic activity |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5519056A (en) |
| EP (1) | EP0552138B1 (en) |
| JP (1) | JP3294652B2 (en) |
| KR (1) | KR100251887B1 (en) |
| AT (1) | ATE151744T1 (en) |
| CA (1) | CA2087084C (en) |
| DE (1) | DE69309725T2 (en) |
| DK (1) | DK0552138T3 (en) |
| ES (1) | ES2101998T3 (en) |
| GR (1) | GR3023163T3 (en) |
| HK (1) | HK1005864A1 (en) |
| IT (1) | IT1254136B (en) |
| ZA (1) | ZA93161B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1258370B (en) * | 1992-03-02 | 1996-02-26 | Sigma Tau Ind Farmaceuti | ESTERS OF L-CARNITINE AND ACIL L-CARNITINE EQUIPPED WITH SELECTIVE MYO-RELAXING ACTIVITY ON THE GASTRO-INTESTINAL APPARATUS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| IT1261828B (en) * | 1993-07-14 | 1996-06-03 | Sigma Tau Ind Farmaceuti | ACIL L-CARNITINE ESTERS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM FOR THE TREATMENT OF THE ENDOTOXIC SHOCK. |
| US5741816A (en) * | 1994-06-20 | 1998-04-21 | Tanabe Seiyaku Co., Ltd. | Hair-growth agent |
| IT1277898B1 (en) * | 1995-08-03 | 1997-11-12 | Mendes Srl | USE OF BASIC AMINO ACIDS, OF ACYL DERIVATIVES OF BASIC AMINO ACIDS AND OF THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR DISEASE PROPHYLAXIS |
| IT1283955B1 (en) * | 1996-03-20 | 1998-05-07 | Sigma Tau Ind Farmaceuti | BIS ALCANOIL ESTERS OF CARNITINE WITH ANTIBACTERIAL, ANTIMICOTIC AND ANTIPROTZOARY ACTIVITY. |
| US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
| CA3132384C (en) * | 2019-03-06 | 2023-09-12 | Xianfeng PENG | Use of .gamma.-quaternary ammonium butyrate compound in preparation of animal feed additive |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH588443A5 (en) * | 1974-09-25 | 1977-06-15 | Lonza Ag | |
| CH596147A5 (en) * | 1974-09-25 | 1978-02-28 | Lonza Ag | |
| IT1116037B (en) * | 1979-04-23 | 1986-02-10 | Sigma Tau Ind Farmaceuti | ACIL CARNITINE ESTERS AND AMIDS THEIR PREPARATION PROCEDURES AND THERAPEUTIC USE |
| IT1147079B (en) * | 1980-05-30 | 1986-11-19 | Sigma Tau Ind Farmacuetiche Ri | ALCOXY-ACYL ESTERS CARNITINE DERIVATIVES PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| IT1170861B (en) * | 1981-03-31 | 1987-06-03 | Sigma Tau Ind Farmaceuti | ESTER OF MERCAPTOACIL-CARNITINE PROCEDURE FOR THEIR PREPARATION AND THERAPEUTIC USE |
| IT1191945B (en) * | 1986-06-04 | 1988-03-31 | Avantgarde Spa | N-ALCHYLAMIDS OF D (+) - CARNITINE EQUIPPED WITH ANTIBACTERIAL ACTIVITY, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM |
| IT1235494B (en) * | 1987-12-02 | 1992-09-04 | Avantgarde Spa | N-ALCHYLAMIDS OF DL AND L (-) CARNITINE EQUIPPED WITH ANTIBACTERIAL ACTIVITY, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM |
| IT1231751B (en) * | 1989-04-12 | 1991-12-21 | Sigma Tau Ind Farmaceuti | PROCEDURE FOR THE PRODUCTION OF R (+) AMMINOCARNITINE AND S (-) AMMINOCARNITINE |
| IT1231944B (en) * | 1989-05-05 | 1992-01-16 | Sigma Tau Ind Farmaceuti | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PROTOZOOSIS, ESPECIALLY OF TRIPASONOMYASIS INCLUDING D-CARNITINE OR AN ALCANOYL DERIVATIVE OF D-CARNITINE |
| IT1240775B (en) * | 1990-02-23 | 1993-12-17 | Sigma Tau Ind Farmaceuti | ESTERS OF L-CARNITINE AND ACYL-L-CARNITINE WITH BETA-HYDROXYBUTIRRIC ACID AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM FOR THE INHIBITION OF NEURONAL DEGENERATION, HEPATIC PROTEOLYSIS AND COMA TREATMENT. |
-
1992
- 1992-01-16 IT ITRM920028A patent/IT1254136B/en active
-
1993
- 1993-01-11 ZA ZA93161A patent/ZA93161B/en unknown
- 1993-01-11 CA CA002087084A patent/CA2087084C/en not_active Expired - Fee Related
- 1993-01-14 JP JP00475793A patent/JP3294652B2/en not_active Expired - Fee Related
- 1993-01-15 DE DE69309725T patent/DE69309725T2/en not_active Expired - Lifetime
- 1993-01-15 AT AT93830010T patent/ATE151744T1/en not_active IP Right Cessation
- 1993-01-15 ES ES93830010T patent/ES2101998T3/en not_active Expired - Lifetime
- 1993-01-15 EP EP93830010A patent/EP0552138B1/en not_active Expired - Lifetime
- 1993-01-15 DK DK93830010.0T patent/DK0552138T3/en active
- 1993-01-16 KR KR1019930000523A patent/KR100251887B1/en not_active IP Right Cessation
-
1994
- 1994-05-26 US US08/250,108 patent/US5519056A/en not_active Expired - Lifetime
-
1995
- 1995-03-24 US US08/409,714 patent/US5525627A/en not_active Expired - Lifetime
-
1997
- 1997-04-17 GR GR960403681T patent/GR3023163T3/en unknown
-
1998
- 1998-06-05 HK HK98104939A patent/HK1005864A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100251887B1 (en) | 2000-05-01 |
| GR3023163T3 (en) | 1997-07-30 |
| DE69309725D1 (en) | 1997-05-22 |
| US5525627A (en) | 1996-06-11 |
| IT1254136B (en) | 1995-09-08 |
| HK1005864A1 (en) | 1999-01-29 |
| JP3294652B2 (en) | 2002-06-24 |
| EP0552138A3 (en) | 1993-10-20 |
| ITRM920028A0 (en) | 1992-01-16 |
| JPH05339219A (en) | 1993-12-21 |
| ITRM920028A1 (en) | 1993-07-16 |
| ES2101998T3 (en) | 1997-07-16 |
| ATE151744T1 (en) | 1997-05-15 |
| US5519056A (en) | 1996-05-21 |
| ZA93161B (en) | 1993-10-06 |
| CA2087084A1 (en) | 1993-07-17 |
| EP0552138B1 (en) | 1997-04-16 |
| DK0552138T3 (en) | 1997-10-20 |
| EP0552138A2 (en) | 1993-07-21 |
| KR930016392A (en) | 1993-08-26 |
| DE69309725T2 (en) | 1997-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR900003020B1 (en) | Method for preparing L-carnitine and alkanoyl L-carnitine salts | |
| EP0491708B1 (en) | Isolating aminoarginine and use to block nitric oxide formation in body | |
| JP4091250B2 (en) | Sphingosine derivatives and pharmaceutical composition | |
| CA2087084C (en) | Esters of acyl carnitines with long-chain aliphatic alcohols and pharmaceutical compositions containing same having antimycotic activity | |
| JP3519108B2 (en) | Esters of L-carnitine and alkanoyl-L-carnitine and pharmaceutical compositions thereof | |
| CA2087085C (en) | Esters of acyl carnitines with long-chain aliphatic alcohols and pharmaceutical compositions containing same having antibacterial activity | |
| US20090186838A1 (en) | Amphotericin Derivatives | |
| US9573882B2 (en) | Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease | |
| US7432398B2 (en) | Inorganic acid salts of sibutramine | |
| RU2548009C2 (en) | Aralkyl bensyl ethers, methods of synthesis thereof, intermediate compounds and their use, methods for treatment and/or prevention, pharmaceutical composition and drug on basis of these compounds | |
| US10071975B2 (en) | Macrocyclic amidinourea derivatives, methods of preparation and uses thereof as chitinase inhibitors | |
| US6180667B1 (en) | Esters of acyl L-carnitines and pharmaceutical compositions containing same for treating endotoxic shock | |
| JPH0223551B2 (en) | ||
| US6225501B1 (en) | Optically active 2-aminotetraline, process for its preparation and pharmaceutical compositions containing same, active in preventing and treating septic shock | |
| US6124352A (en) | Antifungal agents | |
| US5149707A (en) | 1-((2-fluorophenyl)(4-fluorophenyl)phenylmethyl)-1h-imidazole useful as antifungal agent | |
| EP2702033B1 (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease | |
| EP0427242B1 (en) | Azole derivatives and antifungal drugs containing the same as an active component | |
| EP0796841B1 (en) | Bis alkanoyl esters of carnitine having bactericidal, fungicidal and antiprotozoal activity | |
| CN112645926B (en) | A kind of sertraline derivative and its preparation method and application | |
| US4054734A (en) | Amphotericin complexes containing citric acid and calcium | |
| JPS6346073B2 (en) | ||
| JPS63215670A (en) | Imidazole derivative, manufacture and pharmaceutical composition | |
| AU3782593A (en) | Antifungal agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |